Biology and Pathobiology of TDP-43 and Emergent Therapeutic Strategies

Lin Guo and James Shorter

Department of Biochemistry and Biophysics, Perelman School of Medicine at the University of Pennsylvania, Philadelphia, Pennsylvania 19104

Correspondence: jshorter@mail.med.upenn.edu

Cytoplasmic TDP-43 mislocalization and aggregation is a pathological hallmark of amyotrophic lateral sclerosis and frontotemporal lobar degeneration. TDP-43 is an RNA-binding protein (RBP) with a prion-like domain (PrLD) that promotes TDP-43 misfolding. PrLDs possess compositional similarity to canonical prion domains of various yeast proteins, including Sup35. Strikingly, disease-causing TDP-43 mutations reside almost exclusively in the PrLD and can enhance TDP-43 misfolding and toxicity. Another ~70 human RBPs harbor PrLDs, including FUS, TAF15, EWSR1, hnRNPA1, and hnRNPA2, which have surfaced in the etiology of neurodegenerative diseases. Importantly, PrLDs enable RBP function and mediate phase transitions that partition functional ribonucleoprotein compartments. This PrLD activity, however, renders RBPs prone to populating deleterious oligomers or self-templating fibrils that might spread disease, and disease-linked PrLD mutations can exacerbate this risk. Several strategies have emerged to counter TDP-43 proteinopathies, including engineering enhanced protein disaggregases based on Hsp104.

One of the greatest biomedical challenges of our era lies in the daunting reality that there continues to be no effective therapies for several ineluctably fatal and increasingly common neurodegenerative disorders connected with protein misfolding, soluble toxic oligomers, and aberrant protein aggregation (Cushman et al. 2010; Eisenberg and Jucker 2012; Prusiner 2013). One of these debilitating neurodegenerative disorders, amyotrophic lateral sclerosis (ALS), is the most common adult motor neuron disease, afflicting ~2 individuals per 100,000, with typical onset between 50–60 years of age (Robberecht and Philips 2013). Upon progression, ALS is distinguished by an unrelenting

devastation of upper and lower motor neurons (Robberecht and Philips 2013). This neurodegeneration leads to progressive weakness, muscular wasting, and spasticity, which culminates in paralysis, denervation of respiratory muscles, and typically death within ~3–5 years (Robberecht and Philips 2013). There are no effective therapies for ALS, although riluzole can sometimes extend survival by ~2–3 months (Bensimon et al. 1994). Riluzole efficacy is limited and is further compounded by poor central nervous system bioavailability (Jablonski et al. 2014). The lack of treatment options is unacceptable, and we are in urgent need of effective therapeutics (Zinman and Cudkowicz 2011).

Editor: Stanley B. Prusiner

Additional Perspectives on Prion Diseases available at www.perspectivesinmedicine.org

Copyright © 2017 Cold Spring Harbor Laboratory Press; all rights reserved; doi: 10.1101/cshperspect.a024554

Cite this article as *Cold Spring Harb Perspect Med* 2017;7:a024554

L. Guo and J. Shorter

A neuropathological hallmark of ALS is the accumulation of nonamyloid, ubiquitin-positive inclusions in the cytoplasm of degenerating motor neurons and glia (Gros-Louis et al. 2006; Neumann et al. 2006; Pasinelli and Brown 2006; Kwong et al. 2008). The identity of the protein found in these inclusions varies depending on the specific form of ALS. ALS is mostly a sporadic disease (sALS), but ~10% of ALS cases are familial (fALS) (Rowland and Shneider 2001; Renton et al. 2014). Mutations in SOD1, the gene encoding Cu/Zn superoxide dismutase (Gros-Louis et al. 2006; Pasinelli and Brown 2006), have been identified in ~20% of fALS cases for an overall incidence of ~2% (Valentine and Hart 2003). In these cases, SOD1 is found in protein inclusions in afflicted neurons (Rotunno and Bosco 2013). However, whether wild-type (WT) SOD1 misfolds and contributes to sALS remains uncertain (Rotunno and Bosco 2013). Regardless, neurons of ALS patients without SOD1 mutations contain numerous ubiquitin-positive inclusions that are SOD1 negative (Mackenzie et al. 2007), suggesting the presence of additional pathological proteins.

It is now clear that in the vast majority of sALS and fALS cases (~97%) these protein inclusions are comprised of the RNA-binding protein (RBP) TDP-43 (Arai et al. 2006; Neumann et al. 2006; Davidson et al. 2007; Seelaar et al. 2007; Tan et al. 2007; Lagier-Tourenne and Cleveland 2009; Lagier-Tourenne et al. 2010; Ling et al. 2013). Indeed, mutations in eight different genes connected to ALS, *TARDP*, *C9ORF72*, *PGRN*, *VCP*, *UBQLN2*, *ANG*, *OPTN*, and *NIPA1*, result in TDP-43 proteinopathy (Lee et al. 2012; Robberecht and Philips 2013; Renton et al. 2014). However, in some ALS cases, neither TDP-43 nor SOD1 aggregates, but instead another RBP, FUS, forms cytoplasmic aggregates. TDP-43 and FUS pathology are mutually exclusive (Neumann et al. 2009; Vance et al. 2009; Hewitt et al. 2010; Mackenzie et al. 2010; Seelaar et al. 2010). Thus, two ubiquitously expressed and predominantly nuclear RBPs, TDP-43 and FUS, have risen to prominence in ALS (Neumann et al. 2006; Kwiatkowski et al. 2009; Lagier-Tourenne and Cleveland 2009; Vance et al. 2009; Lagier-Tou-

renne et al. 2010; Da Cruz and Cleveland 2011; Robberecht and Philips 2013). Importantly, mutations in the genes that encode TDP-43 and FUS cause ~10% of fALS cases (Da Cruz and Cleveland 2011; Renton et al. 2014). TDP-43 and FUS are of particular interest because they are aggregated in the cytoplasm of sALS cases (Neumann et al. 2006; Pesiridis et al. 2009; Deng et al. 2010; Hewitt et al. 2010; Rademakers et al. 2010; Fujita et al. 2011; see also Mackenzie and Neumann 2017; Nonaka and Hasegawa 2017).

It is important to note that TDP-43, FUS, and SOD1 are not the only proteins that misfold and aggregate in ALS. Depending on the precise form of the disease, in addition to TDP-43 pathology, other RBPs can also form inclusions, including TAF15, EWSR1, hnRNP A1, hnRNP A2, and hnRNP A3 (Couthouis et al. 2011, 2012; Kim et al. 2013; Mori et al. 2013b). Moreover, the most common genetic cause of ALS is a massive expansion of the GGGGCC hexanucleotide repeat in the first intron of the *C9ORF72* gene (DeJesus-Hernandez et al. 2011; Renton et al. 2011, 2014). The first intron of the *C9ORF72* gene contains a polymorphic hexanucleotide repeat, GGGGCC (DeJesus-Hernandez et al. 2011; Renton et al. 2011). The repeat tract length in unaffected individuals (although variable) is typically between ~5 and 10 repeats and is almost always fewer than ~23 repeats (DeJesus-Hernandez et al. 2011; Renton et al. 2011; Rohrer et al. 2015). In *C9ORF72*-ALS cases, the hexanucleotide repeat tract is expanded to hundreds or even thousands of repeats, which cause impairments in nucleocytoplasmic transport (Acharya et al. 2006; DeJesus-Hernandez et al. 2011; Renton et al. 2011, 2014; Fox and Tibbetts 2015; Freibaum et al. 2015; Jovicic et al. 2015; Rohrer et al. 2015; Zhang et al. 2015). Intriguingly, the pathogenic GGGGCC repeat expansion can be translated, even in the absence of an ATG start codon and even though it is located in a noncoding region of *C9ORF72* (Mori et al. 2013a,c). This unconventional repeat-associated non-ATG translation (Zu et al. 2011) occurs in all sense and antisense reading frames, producing polymers of the predicted dipeptides (sense: GGG GCC = Gly-Ala; GGG CCG =

Gly-Pro; GGCCGG = Gly-Arg; antisense: CCC CGG = Pro-Arg; CCC GGC = Pro-Gly; CCG GCC = Pro-Ala) (Mackenzie et al. 2013; Mori et al. 2013a,c; Zu et al. 2013). Remarkably, these various dipeptide repeat proteins form cytoplasmic inclusions in neurons of ALS and frontotemporal lobar degeneration (FTLD) patients with the *C9ORF72* GGGGCC repeat expansion mutation, but not in ALS cases without the *C9ORF72* GGGGCC repeat expansion (Mackenzie et al. 2013; Mori et al. 2013a,c; Zu et al. 2013). Moreover, poly-GA, poly-GR, and poly-PR are highly toxic in model systems independent of the GGGGCC repeat expansion, and poly-GR and poly-PR can directly impair nucleocytoplasmic transport (Kwon et al. 2014; May et al. 2014; Mizielinska et al. 2014; Paul and Gitler 2014; Wen et al. 2014; Jovicic et al. 2015; Tao et al. 2015; Tran et al. 2015). Thus, multiple proteins are misfolded and aggregated in ALS, and the precise set of affected proteins depends on the underlying cause of disease.

Just as other proteins can be aggregated in ALS, TDP-43 misfolds and aggregates in other neurodegenerative diseases as well. Indeed, pathology and genetics have also connected TDP-43 misfolding to a subset of FTLD cases (FTLD-TDP) (Arai et al. 2006; Neumann et al. 2006; Mackenzie et al. 2010; Robberecht and Philips 2013). FTLD is a devastating neurodegenerative disorder characterized by progressive loss of neurons in the frontal and temporal lobes (Irwin et al. 2015). This neurodegeneration predominantly affects behavior, social awareness, and language and is marked by a severe deterioration in functioning and typically death ~8 years after the onset of symptoms (Irwin et al. 2015). As with ALS, in FTLD-TDP, TDP-43 is mislocalized to cytoplasmic inclusions and depleted from the nucleus in afflicted neurons (Arai et al. 2006; Neumann et al. 2009; Mackenzie et al. 2010; Irwin et al. 2015). Interestingly, sometimes neurons in the prefrontal and temporal cortex are also affected in ALS (~15% of cases), and, likewise, FTLD can present with ALS (~15% of cases) (Robberecht and Philips 2013). Thus, ALS and FTLD appear to represent opposite ends of the clinical spectrum of a single disease (Geser et al. 2009; Robberecht and

TDP-43: Biology, Pathobiology, and Therapeutics

Philips 2013). Prominent TDP-43 cytoplasmic mislocalization and aggregation is also evident in Perry syndrome, Alexander disease, and multisystem proteinopathy (MSP), also known as inclusion-body myopathy with Paget's disease of bone and frontotemporal dementia with ALS (IBMPFD/ALS) (Weihl et al. 2008; Chen-Plotkin et al. 2010; Benatar et al. 2013; Kim et al. 2013; Walker et al. 2014). Remarkably, TDP-43 pathology is a secondary feature of several other neurodegenerative disorders, including Alzheimer's disease (AD), Lewy body (LB)-related diseases (e.g., Parkinson's disease), and Huntington's disease (Amador-Ortiz et al. 2007; Nakashima-Yasuda et al. 2007; Schwab et al. 2008; Uryu et al. 2008; Chen-Plotkin et al. 2010; Josephs et al. 2014a, 2016). TDP-43 lesions appear to worsen several clinical and pathological parameters observed in AD and LB-related disorders, indicating combinatorial effects (Nakashima-Yasuda et al. 2007; Josephs et al. 2014b; Jung et al. 2014). Collectively, these advances indicate that TDP-43 misfolding likely contributes to a broad range of neurodegenerative conditions and could be an important therapeutic target. Here, we review the biology and pathobiology of TDP-43 and consider possible therapeutic strategies to mitigate TDP-43 misfolding and toxicity in disease.

TDP-43 PERFORMS DIVERSE FUNCTIONS IN THE NUCLEUS AND CYTOPLASM

TDP-43 is a 414 amino acid RBP bearing two RNA-recognition motifs (RRMs): RRM1 (amino acids 105–169) and RRM2 (amino acids 193–253) (Fig. 1A) (Buratti and Baralle 2001). TDP-43 displays specificity for UG-rich RNA and TG-rich DNA (Buratti and Baralle 2001; Polymenidou et al. 2011; Lukavsky et al. 2013; Qin et al. 2014). RRM2 contains a nuclear export sequence (NES; amino acids 239–250) (Fig. 1A) (Winton et al. 2008). The RRM2s are flanked on the N-terminal side by an N-terminal domain (NTD; amino acids 1–78) that adopts a ubiquitin-like fold and a canonical nuclear localization sequence (NLS; amino acids 82–98), and they are flanked on the C-terminal side by a low complexity prion-like domain (PrLD; amino

L. Guo and J. Shorter

Figure 1. TDP-43 structure. (A) Domain architecture of TDP-43. Domain boundaries are numbered according to the full-length protein sequence. (B) Overlay of the TDP-43 N-terminal domain (NTD) structure (blue) and ubiquitin (yellow; PDB ID code 3EHV) (Qin et al. 2014). (C) Ribbon representation of the structure of the TDP-43 RNA-recognition motif (RRM) construct (amino acids 102–269) in complex with AUG12 RNA (PDB ID code 4BS2) (Lukavsky et al. 2013).

acids 277–414) (Fig. 1A) (Winton et al. 2008; Cushman et al. 2010; Fuentealba et al. 2010; Couthouis et al. 2011; King et al. 2012; Li et al. 2013; Qin et al. 2014; Mompean et al. 2016).

TDP-43 is an essential gene in mammals, zebrafish, and flies (but curiously is not essential in *Caenorhabditis elegans*). It is broadly expressed and, under normal conditions, resides predominantly in the nucleus but shuttles to and from the cytoplasm (Ayala et al. 2008; Winton et al. 2008; Feiguin et al. 2009; Lu et al. 2009; Chiang et al. 2010; Kraemer et al. 2010; Sephton et al. 2010; Zhang et al. 2012; Schmid et al. 2013). TDP-43 expression level is very tightly regulated (Ayala et al. 2011; Polymenidou et al. 2011). Indeed, overexpression of TDP-43 is connected with FTL (Gitcho et al. 2009) and is detrimental in diverse model systems (Johnson et al. 2008; Ash et al. 2010; Elden et al. 2010; Tsai et al. 2010; Xu et al. 2010; Estes et al. 2011; Igaz et al. 2011; Zhang et al. 2011). TDP-43

directly regulates its own expression by binding to the 3'UTR of its own mRNA and promoting its degradation (Ayala et al. 2011; Polymenidou et al. 2011; Avendano-Vazquez et al. 2012).

In the nucleus, TDP-43 performs several important functions (Ling et al. 2013). It engages promoter regions of genes and can repress transcription (Ou et al. 1995; Acharya et al. 2006; Lalmansingh et al. 2011). As well as directly binding DNA, TDP-43 physically interacts with various proteins involved in transcription (e.g., methyl-CpG-binding protein 2), although proteomic analysis suggests that TDP-43 predominantly interacts with proteins involved in splicing and translation (Freibaum et al. 2010; Sephton et al. 2011). However, the precise set of genes that are regulated at the transcriptional level by TDP-43 remains unclear. At the RNA level, TDP-43 performs diverse functions in the nucleus, which include splicing and inhibition of exon recognition,

long intron binding and stabilization, micro-RNA biogenesis, co-transcriptional limitation of double-stranded RNA formation, inhibition of specific RNA editing events, and binding long noncoding RNA (Buratti and Baralle 2001; Buratti et al. 2004; Ayala et al. 2006; Polymenidou et al. 2011; Kawahara and Mieda-Sato 2012; Lagier-Tourenne et al. 2012; Ling et al. 2013; Saldi et al. 2014; Ling et al. 2015). TDP-43 also performs critical RNA-binding modalities in the cytoplasm related to RNA transport, translation, and stress-granule formation (Liu-Yesucevitz et al. 2010; Nishimoto et al. 2010; McDonald et al. 2011; Li et al. 2013; Ling et al. 2013; Alami et al. 2014; Coyne et al. 2014; Liu-Yesucevitz et al. 2014). These collective nuclear and cytoplasmic functions are facilitated by the RNA-binding activity of TDP-43 coupled with interactions with numerous hnRNPs (e.g., hnRNPA1 and A2), microprocessor proteins (e.g., dicer and drosha), and splicing factors (e.g., PSE, splicing factor 3a, PTBP2) (Buratti et al. 2005; D'Ambrogio et al. 2009; Freibaum et al. 2010; Ling et al. 2010; Sephton et al. 2011; Kawahara and Mieda-Sato 2012). It is estimated that TDP-43 binds to >6000 RNA targets in the brain, thereby impacting ~30% of the transcriptome (Polymenidou et al. 2011; Tollervey et al. 2011). In the brain, TDP-43 affects the splicing of ~950 mRNAs and engages the 3'UTR of >1000 mRNAs (Polymenidou et al. 2011; Tollervey et al. 2011). TDP-43 also engages and stabilizes very long introns in various pre-mRNAs and is estimated to affect the levels of >600 mRNAs in the mammalian nervous system (Polymenidou et al. 2011; Tollervey et al. 2011).

TDP-43 STRUCTURE AND FUNCTION

The structure of full-length TDP-43 remains unknown, and so precisely how TDP-43 accomplishes these diverse tasks remains uncertain as well. Nonetheless, biochemical and functional studies have yielded important insights. Several lines of evidence suggest that TDP-43 must form homodimers for optimal functionality, and dimerization appears to be mediated by the first 10 amino acids of the TDP-43 NTD

TDP-43: Biology, Pathobiology, and Therapeutics

(Fig. 1A) (Johnson et al. 2009; Shiina et al. 2010; Wang et al. 2013; Zhang et al. 2013; Kuo et al. 2014; Sun et al. 2014). Further domain requirements for TDP-43 activity have been elucidated in various functional studies. For example, considerable interplay between RRM1 and RRM2 contributes to complex formation with RNA (Buratti and Baralle 2001; Lukavsky et al. 2013). Highly conserved phenylalanines in RRM1 (F147 and F149) and RRM2 (F194, F229, and F231) engage RNA directly, although RRM2 makes a weaker contribution to the overall TDP-43 RNA-binding affinity (Buratti and Baralle 2001; Lukavsky et al. 2013). In contrast, the C-terminal PrLD is not typically required for TDP-43 to bind RNA or DNA, although in isolation the TDP-43 PrLD can directly bind single-stranded DNA (Lim et al. 2016). Nonetheless, the PrLD is critical for TDP-43 activity in alternative splicing of some mRNAs and mediates protein–protein interactions with other hnRNPs, including hnRNPA1, A2, and FUS, as well as components of the dicer and drosha complexes (Ayala et al. 2005; Buratti et al. 2005; D'Ambrogio et al. 2009; Kim et al. 2010; Kawahara and Mieda-Sato 2012). However, alternative splicing of other mRNAs depends strictly on RRM1, whereas RRM2 and the PrLD are less important (Fiesel et al. 2012). Likewise, TDP-43 activity in transcriptional repression can be mediated solely by RRM1 (Lalmansingh et al. 2011), whereas TDP-43 recruitment to stress granules requires RRM1 and the PrLD (Bentmann et al. 2012). Thus, a picture is gradually emerging in which the complex multidomain architecture of TDP-43 is deployed in various ways to enable specific functions.

Structural studies of isolated TDP-43 domains have also started to yield key insights. For example, initial studies suggested that the isolated NTD (amino acids 1–78) adopts a novel ubiquitin-like fold (Fig. 1B), even though the primary sequence bears little resemblance to ubiquitin (Qin et al. 2014). The significance of this putative ubiquitin-like fold in the TDP-43 NTD remains unclear, but ubiquitin-like domains in other proteins can mediate diverse functions, including direct binding to the proteasome (Madsen et al. 2007; Grabbe and Dikic

L. Guo and J. Shorter

2009). The TDP-43 NTD engages single-stranded TG-rich DNA in a sequence-specific manner, and addition of UG-rich RNA may induce aggregation of the TDP-43 NTD (Qin et al. 2014). The role of the potential ubiquitin-like fold in TDP-43 function and disease warrants further study and connects TDP-43 to another ALS disease protein, ubiquilin-2, which also harbors a ubiquitin-like domain (Hanson et al. 2010; Deng et al. 2011).

More recent studies, however, suggest that the TDP-43 NTD contains additional structural elements, including two β -strands that form a β -hairpin, which is not found in the ubiquitin fold (Mompean et al. 2016). Thus, the TDP-43 NTD may more closely resemble the C-terminal Dix domain of Axin 1 (Mompean et al. 2016). This finding suggests that the TDP-43 NTD may be more likely to bind cationic protein structures rather than nucleic acids (Mompean et al. 2016).

The structure of a TDP-43 construct comprising both RRM1 (amino acids 102–269) bound to UG-rich RNA oligonucleotide, AUG12 (5'-GUGUGAAUGAAU-3'), revealed that RRM1 and RRM2 adopt a canonical RRM fold ($\beta 1\alpha 1\beta 2\beta 3\alpha 2\beta 4$) with an additional β -hairpin ($\beta 3'\beta 3''$) inserted between $\alpha 2$ and $\beta 4$ (Fig. 1C) (Lukavsky et al. 2013). The β -hairpin insertion creates an expanded β -sheet surface accessible for RNA binding (Fig. 1C) (Lukavsky et al. 2013). An extended, positively charged groove on the β -sheet surface accommodates the AUG12 RNA in a single-stranded conformation in which 10 of the 12 nucleotides directly contact the protein (Lukavsky et al. 2013). Importantly, six of these G or U nucleotides are recognized sequence specifically, which explains the specificity of TDP-43 for UG-rich RNA (Lukavsky et al. 2013). The RNA is bound in a 5' to 3' direction from RRM1 to RRM2 (Fig. 1C), in contrast to several other tandem RRM proteins that engage RNA in a 5' to 3' direction from RRM2 to RRM1 (Lukavsky et al. 2013). A central G nucleotide engages both RRM1 and RRM2 and thereby stabilizes a specific tandem RRM arrangement, which enables TDP-43 to bind RNA and promote splicing activity (Lukavsky et al. 2013). Indeed, splicing repression

by TDP-43 is mediated by sequence specificity for UG-rich RNA encoded by both RRM1, high-affinity RNA binding by RRM1, and exact spatial positioning of the RRM1s relative to one another (Lukavsky et al. 2013).

The C-terminal, low complexity PrLD of TDP-43 (amino acids 277–414) is enriched in uncharged polar amino acids and glycine and contains two tracts (amino acids 277–293 and 346–378) that are predicted to be intrinsically unfolded (Cushman et al. 2010; King et al. 2012). The unusual amino acid composition of the PrLD resembles that of canonical prion domains of various yeast proteins, including Sup35 and Mot3 (Cushman et al. 2010; King et al. 2012; Li et al. 2013). In Sup35 and Mot3, the prion domain can switch from an intrinsically unfolded state to a prion conformation (i.e., self-templating and infectious fibrils possessing a cross- β -amyloid conformation) (Shorter and Lindquist 2005; Alberti et al. 2009; Halfmann et al. 2012). In yeast, Sup35 and Mot3 prions can be beneficial (Shorter and Lindquist 2005; Halfmann et al. 2012). Thus, by analogy, TDP-43 might also access beneficial prion or amyloid states, which might be involved in RNA-based cellular memories or epigenetic states connected to transcriptional memory (Shorter and Lindquist 2005; King et al. 2012). Here, precedent is provided by another RBP, CPEB, which forms prions via a related prion domain that may underpin long-term potentiation (Si et al. 2003a,b, 2010; Shorter and Lindquist 2005; Majumdar et al. 2012; Drisaldi et al. 2015; Fioriti et al. 2015; Khan et al. 2015; Stephan et al. 2015). Likewise, another RBP with a prion domain, Rim4, forms functional amyloid-like structures that repress translation of cyclin CLB3 in meiosis I, thereby ensuring homologous chromosome segregation (Berchowitz et al. 2015; Ford and Shorter 2015). Regardless, the TDP-43 PrLD is critical for various TDP-43 functions and mediates important protein–protein interactions (Ayala et al. 2005; Buratti et al. 2005; D'Ambrogio et al. 2009; Kim et al. 2010; Kawahara and Mieda-Sato 2012). The PrLD of TDP-43 mediates phase transitions to higher-order liquid- or gel-like multimeric states that likely help organize func-

tional and highly dynamic TDP-43 RNP granules (Johnson et al. 2009; Liu-Yesucevitz et al. 2011; Han et al. 2012; Kato et al. 2012; Wang et al. 2012; Li et al. 2013; Saini and Chauhan 2014; Guo and Shorter 2015; Lin et al. 2015; Molliex et al. 2015). Specifically, the phase transition of the PrLD of TDP-43 is mediated by an α -helix and conserved residues in the 321–340 region (Conicella et al. 2016). Remarkably, the PrLD of TDP-43 can be replaced with the prion domain of Sup35, yielding a TDP-43 hybrid protein that can still assemble into dynamic granules and function in alternative splicing (Wang et al. 2012). The dynamic phase-transitioning behavior mediated by the TDP-43 PrLD enables rapid assembly and disassembly of RNP granules, but is likely to simultaneously render TDP-43 prone to accessing deleterious misfolded states or pathological aggregates that contribute to disease (Hart and Gitler 2012; King et al. 2012; Buchan et al. 2013; Li et al. 2013; Ramaswami et al. 2013; Guo and Shorter 2015; Lin et al. 2015; Molliex et al. 2015).

TDP-43 MISFOLDING AND PATHOGENESIS IN ALS

TDP-43 forms pathological inclusions in degenerating neurons of ALS patients (Arai et al. 2006; Neumann et al. 2006). The inclusions are typically cytoplasmic, and, consequently, TDP-43 is depleted from the nucleus (Arai et al. 2006; Neumann et al. 2006). However, nuclear TDP-43 inclusions can also be observed in neurons and glia (Arai et al. 2006; Neumann et al. 2006). In ALS, TDP-43 shows abnormal phosphorylation, ubiquitylation, aberrant lysine acetylation, and accumulation of C-terminal fragments comprising the PrLD and a portion of RRM2 (Arai et al. 2006; Neumann et al. 2006; Cohen et al. 2015). More than 40 mutations in TDP-43 are now connected to sporadic and familial ALS as well as FTLD-TDP, and, remarkably, the vast majority of these mutations reside in the PrLD (Gitcho et al. 2008; Kabashi et al. 2008; Sreedharan et al. 2008; Pesiridis et al. 2009; Lattante et al. 2013). The loss of nuclear TDP-43 in degenerating neurons of ALS patients indicates that a loss of nuclear TDP-43 function likely

TDP-43: Biology, Pathobiology, and Therapeutics

contributes to disease (Lee et al. 2012; Li et al. 2013; Ling et al. 2013). Moreover, the sequestration of TDP-43 in misfolded structures in the cytoplasm also indicates a loss of cytoplasmic function as well as a toxic gain of function (Lee et al. 2012; Li et al. 2013; Ling et al. 2013). Indeed, TDP-43 clearance by autophagy induction mitigates neurodegeneration (Barmada et al. 2014; Scotter et al. 2014). In our view, it seems probable that TDP-43 pathogenesis in ALS reflects a combination of loss-of-function and gain-of-toxic function phenotypes (Lee et al. 2012; Li et al. 2013; Ling et al. 2013).

In isolation, pure TDP-43 is intrinsically aggregation prone and upon agitation rapidly assembles into pore-shaped oligomers and fibrils (Johnson et al. 2009; Couthouis et al. 2011; Fang et al. 2014). The pore-shaped TDP-43 oligomers bear remarkable ultrastructural similarity to toxic oligomers formed by other neurodegenerative disease proteins, including α -synuclein and A β (Lashuel et al. 2002). An oligomer-specific antibody, A11, which detects toxic oligomers formed by diverse neurodegenerative disease proteins (Kayed et al. 2003), also recognizes these pure TDP-43 oligomers (Fang et al. 2014). Moreover, purified TDP-43 oligomers are toxic to neurons in culture and also display localized neurotoxicity in vivo when injected directly into the mouse hippocampus (Fang et al. 2014). Similar TDP-43 oligomers can also be detected in the brains of transgenic TDP-43 mice and FTLD-TDP patients, but not in controls (Fang et al. 2014). These findings indicate that TDP-43 oligomers might contribute to pathogenesis.

It is likely, however, that components of the proteostasis network, including endogenous RNA substrates and interacting proteins, prevent rapid TDP-43 misfolding in vivo. Indeed, RNA ligands, including oligonucleotides from the 3'UTR of the TDP-43 mRNA, prevent TDP-43 aggregation in vitro and preserve TDP-43 in its native dimeric state (Huang et al. 2013; Sun et al. 2014). Accordingly, lysine acetylation events that impair RNA binding or mutation of conserved phenylalanines in the RRM1 (especially RRM1) that engage RNA promote TDP-43 aggregation in cells (Elden et al. 2010;

L. Guo and J. Shorter

Wang et al. 2012; Cohen et al. 2015). However, it is critical to note that simple TDP-43 aggregation alone does not suffice to confer toxicity in multiple model systems (Johnson et al. 2008; Elden et al. 2010; Voigt et al. 2010). Thus, overexpression of RNA-binding defective TDP-43 variants leads to TDP-43 misfolding and aggregation, but not toxicity (Johnson et al. 2008; Elden et al. 2010; Voigt et al. 2010). These findings suggest that RNA binding by TDP-43 and TDP-43 misfolding are required for toxicity (Johnson et al. 2008; Elden et al. 2010; Voigt et al. 2010). Hence, interfering with either RNA binding by TDP-43 or TDP-43 misfolding might be sufficient to alleviate toxicity.

Why is the combination of RNA binding and protein misfolding so critical for TDP-43 toxicity? Misfolded forms of TDP-43 might sequester essential RNA molecules, RBPs, or both to promote neurodegeneration (Polymenidou et al. 2011; Tollervey et al. 2011; Armakola et al. 2012). In fact, misfolding might cause TDP-43 to bind RNA more tightly, as with *Aplysia* CPEB (Si et al. 2003b). RNA could stabilize or divert TDP-43 to access specific misfolded forms that are particularly neurotoxic. Indeed, different RNAs might even engender TDP-43 to fold into different misfolded forms or fibril “strains,” some of which might be extremely toxic. In this regard, it is interesting to note that RNA can enable mammalian PrP to more readily access infectious conformations (Deleault et al. 2003; Wang et al. 2010, 2011a,b). Thus, perhaps certain RNAs enable TDP-43 to populate specific, deleterious self-templating conformers. Further studies at the pure protein level are necessary to test these hypotheses and to define misfolding trajectories followed by TDP-43 under different conditions.

Importantly, the TDP-43 PrLD drives TDP-43 misfolding, as deletion of the PrLD prevents spontaneous TDP-43 aggregation in isolation (Johnson et al. 2009). Indeed, deletion of a short segment (amino acids 311–320) within the PrLD precludes TDP-43 aggregation in vitro (Saini and Chauhan 2011). PrLD deletion prevents aberrant TDP-43 misfolding events and toxicity in various model systems (Johnson et al. 2008; Ash et al. 2010; Wang et al. 2012).

Moreover, increased expression of C-terminal fragments of TDP-43 that harbor the PrLD confers toxicity and cytoplasmic TDP-43 aggregation in several settings (Johnson et al. 2008; Zhang et al. 2009; Ash et al. 2010; Yang et al. 2010; Pesiridis et al. 2011; Caccamo et al. 2012). Interestingly, although not required for misfolding in vitro or in yeast (Johnson et al. 2008, 2009), determinants in the TDP-43 NTD also contribute to the recruitment of full-length TDP-43 to the aggregated state and its subsequent inactivation (Budini et al. 2015; Romano et al. 2015). Moreover, under some conditions in mammalian cells, the N-terminal 10 residues of TDP-43 are important for the cytoplasmic aggregation of TDP-43 variants bearing a mutated NLS that precludes nuclear import (Zhang et al. 2013). These findings raise the possibility that TDP-43 might form a spectrum of distinct misfolded, aggregated structures, which can vary depending on the precise conditions.

Remarkably, nearly all the ALS-linked mutations in TDP-43 are located in the PrLD (Latant et al. 2013). A yeast model of TDP-43 proteinopathy combined with pure protein biochemistry suggests that ALS-linked TDP-43 variants fall into two distinct classes (Johnson et al. 2008, 2009). The first class of ALS-linked TDP-43 mutations has no effect on TDP-43 misfolding in vitro and does not promote toxicity in yeast and includes G294A (Johnson et al. 2009). These findings suggest that some ALS-linked TDP-43 mutations in the PrLD do not impact misfolding events directly. The second class of ALS-linked TDP-43 mutations, including Q331K and M337V, accelerates spontaneous TDP-43 misfolding in isolation and potentiates TDP-43 toxicity in yeast (Johnson et al. 2009). These mutations also alter the phase-separation properties of TDP-43 (Conicella et al. 2016; Schmidt and Rohatgi 2016). Moreover, Q331K shows greater toxicity than WT TDP-43 in *Drosophila* (Elden et al. 2010). Indeed, similar effects of ALS-linked mutations in promoting TDP-43 misfolding and toxicity have been uncovered in diverse model systems, including pure protein settings, cell culture, flies, chicken embryos, mice, and rats (Sreedharan et al. 2008;

Zhang et al. 2009; Barmada et al. 2010; Kabashi et al. 2010; Li et al. 2010; Ritson et al. 2010; Guo et al. 2011; Lim et al. 2016). Collectively, these findings indicate that a subset of ALS-linked TDP-43 variants likely cause disease by a gain-of-toxic function mechanism (Gitler and Shorter 2011).

It is important to note, however, that loss of TDP-43 function also plays a key role in pathogenesis, as selective depletion of TDP-43 from neurons causes neurodegeneration in vivo (Feiguin et al. 2009; Wu et al. 2012; Iguchi et al. 2013). Moreover, depletion of TDP-43 from mouse embryonic stem cells causes a defect in repression of cryptic exons and cell death (Ling et al. 2015). Loss of nuclear function is anticipated from the nuclear depletion of TDP-43, as is loss of cytoplasmic function because of TDP-43 sequestration in inclusions (Lee et al. 2012; Li et al. 2013; Ling et al. 2013). However, ALS-linked TDP-43 mutations can also cause loss of cytoplasmic TDP-43 function in the spatially restricted context of functional mRNP granules (Alami et al. 2014; Jovicic and Gitler 2014). TDP-43 assembles into cytoplasmic mRNP granules in neurons that show bidirectional, microtubule-dependent transport, which facilitates delivery of target mRNAs to distal neuronal compartments (Alami et al. 2014; Jovicic and Gitler 2014). The ALS-linked TDP-43 variants A315T, M337V, and G298S impair this transport activity, suggesting a partial loss of this cytoplasmic function (Alami et al. 2014; Jovicic and Gitler 2014). Thus, altered mRNP granule assembly or dynamics might contribute to neurodegeneration, and restoring functional RNP granule assembly, dynamics, or disassembly may have therapeutic utility (Li et al. 2013; Ramaswami et al. 2013).

Does TDP-43 access a bona fide prion or prion-like form? An interesting facet of ALS is the gradual spread of pathology from initiating sites to contiguous areas of the brain, which involves multiple cell types (Ravits and La Spada 2009). This pattern of disease spread has led to suggestions that a prion-like agent might be involved (Cushman et al. 2010; Polymenidou and Cleveland 2011, 2012; Udan and Baloh 2011; King et al. 2012; Grad et al. 2015;

TDP-43: Biology, Pathobiology, and Therapeutics

Maniecka and Polymenidou 2015; Josephs et al. 2016). Intriguingly, phosphorylated TDP-43 pathology in ALS has been interpreted to spread in a sequential manner with highly discernible stages that might indicate involvement of axonal pathways (Brettschneider et al. 2013, 2014; Ludolph and Brettschneider 2015).

However, does the PrLD of TDP-43 enable TDP-43 to access an infectious, self-templating amyloid form just like the prion domains of various yeast prion proteins (Shorter and Lindquist 2005)? Full-length TDP-43 purified under native conditions does not appear to readily form a classic amyloid structure recognized by diagnostic amyloid dyes such as thioflavin T or Congo red (Johnson et al. 2009). Likewise, ALS pathology is typically devoid of amyloid structures recognized by these dyes (Neumann et al. 2007), although, in a subset of ALS cases, TDP-43 skeins are recognized by thioflavin S and contain TDP-43 fibrils (Robinson et al. 2013). Short, synthetic peptides derived from the PrLD of TDP-43 can access toxic amyloid conformers (Chen et al. 2010; Guo et al. 2011). However, these short peptides do not occur naturally, and so their relevance is uncertain. Moreover, the vast majority of proteins harbor short peptides able to form amyloid in isolation (Goldschmidt et al. 2010). Intriguingly, TDP-43 and C-terminal TDP-43 fragments (193–414) purified under denaturing conditions can form fibrils that do not bind thioflavin T, but seed TDP-43 aggregation in vitro and in cell culture (Furukawa et al. 2011). Moreover, detergent-insoluble fractions purified from ALS brains containing TDP-43 fibrils induced aggregation of endogenous TDP-43 in neuroblastoma cells in culture (Nonaka et al. 2013). Thus, TDP-43 may indeed be able to access a prion-like conformation, which may even be transmitted across axon terminals (Feiler et al. 2015). However, convincing evidence of transmissible prion-like TDP-43 conformers will require their assembly from purely synthetic protein followed by induction of neurodegenerative disease upon injection into transgenic or WT mice, as has been achieved with PrP and α -synuclein (Legname et al. 2004; Colby et al. 2009; Wang et al. 2010, 2011a,b; Luk et al. 2012).

L. Guo and J. Shorter

AN RBP WITH A PrLD HAS EMERGED IN SEVERAL NEURODEGENERATIVE DISEASE SETTINGS

In addition to TDP-43, another ~70 human RBPs harbor PrLDs of similar low complexity sequence and amino acid composition to domains that drive prionogenesis of yeast proteins like Sup35 (Cushman et al. 2010; King et al. 2012; Kim et al. 2013; March et al. 2016). These include FUS, TAF15, EWSR1, hnRNPA1, and hnRNPA2/B1, which have all surfaced as misfolded RBPs in the etiology of neurodegenerative diseases (Kwiatkowski et al. 2009; Vance et al. 2009; Cushman et al. 2010; Lagier-Tourenne et al. 2010; Couthouis et al. 2011, 2012, 2014; Neumann et al. 2011; Sun et al. 2011; King et al. 2012; Mackenzie and Neumann 2012; Kim et al. 2013; Ling et al. 2013; March et al. 2016). It is now widely thought that PrLDs enable RBP function and mediate phase transitions that partition functional ribonucleoprotein compartments (Kato et al. 2012; Li et al. 2013; Ramaswami et al. 2013). This PrLD activity, however, renders RBPs prone to populating deleterious oligomers or self-templating fibrils that might spread disease, and disease-linked PrLD mutations can exacerbate this risk (Kim et al. 2013; Ramaswami et al. 2013; Shorter and Taylor 2013). One particularly clear case involves mutations in hnRNPA1 and hnRNPA2 that underpin MSP (Kim et al. 2013; Shorter and Taylor 2013). Here, a conserved gatekeeper aspartate residue in the exact same position of the hnRNPA1 or hnRNPA2/B1 PrLD is mutated to valine (Kim et al. 2013; Shorter and Taylor 2013). Thus, the D262V mutation in hnRNPA1 or the D290V mutation in hnRNPA2 introduces a potent amyloidogenic steric zipper into the PrLD that accelerates hnRNP misfolding into self-templating fibrils and cytoplasmic-inclusion formation (Kim et al. 2013; Shorter and Taylor 2013). Remarkably, very similar mutations in the PrLD of hnRNPD, D378N, or D378H have now been linked to limb-girdle muscular dystrophy type 1G (Vieira et al. 2014). We predict that human proteins bearing PrLDs will continue to emerge in the etiology of protein-misfolding disorders and degenerative diseases (King et al. 2012; March et al. 2016).

STABILIZING NATIVE TDP-43 DIMERS AS A THERAPEUTIC STRATEGY

In the closing sections of this review, we consider possible therapeutic approaches to combat TDP-43 proteinopathies. The only small-molecule drug treatment available for neurodegenerative disorders that targets the underlying protein-misfolding events that cause disease is Tafamidis (Bulawa et al. 2012; Nencetti et al. 2013). Tafamidis is used to treat transthyretin (TTR)-related hereditary amyloidosis (also known as familial amyloid polyneuropathy), a rare but deadly neurodegenerative disease (Bulawa et al. 2012; Nencetti et al. 2013). Tafamidis functions by stabilizing the correctly folded, native tetramer of TTR, thereby preventing TTR tetramer dissociation, which is the first and rate-limiting step of TTR amyloidogenesis (Hammarstrom et al. 2003; Hurshman et al. 2004; Bulawa et al. 2012). Based on this strong precedent, a potentially powerful therapeutic strategy might be to isolate small molecules or other agents that stabilize the native dimeric state of TDP-43 and thereby prevent misfolding (Zhang et al. 2013). Interestingly, endogenous RNA ligands may already provide this activity (Sun et al. 2014), which could be mimicked by specific aptamers.

RESTORING NUCLEAR TDP-43 VIA MODULATION OF NUCLEAR TRANSPORT

TDP-43 depletion from the nucleus is widely thought to be a critical event in pathogenesis (Lee et al. 2012; Li et al. 2013; Ling et al. 2013). One potential therapeutic strategy could be to restore nuclear TDP-43 by inhibiting TDP-43 nuclear export or stimulating TDP-43 nuclear import. Thus, small molecules that inhibit expression of nuclear export factors or increase expression of nuclear import factors could be useful. Likewise, small-molecule inhibitors of nuclear export or small-molecule enhancers of nuclear import could be advantageous. Encouragingly, orally administered reversible inhibitors of the nuclear export factor Crm1 (which decodes the TDP-43 NES) signif-

icantly attenuated mouse models of inflammatory demyelination and other models of axonal damage (Haines et al. 2015). Importantly, in neurons, Crm1 inhibitors prevented nuclear export of factors connected with axonal damage while retaining transcription factors in the nucleus that promote neuroprotection (Haines et al. 2015). It will be interesting to test whether these Crm1 inhibitors display efficacy against neuronal or animal models of TDP-43 proteinopathy.

INHIBITING OR REDUCING EXPRESSION OF ATAXIN 2

Genome-wide screens in yeast have uncovered a number of genetic suppressors of TDP-43 toxicity (Elden et al. 2010; Sun et al. 2011; Armakola et al. 2012). Among these, deletion suppressors are of particular interest because they could be targeted by small-molecule inhibitors or siRNA or antisense strategies. Deletion of the yeast homolog of Ataxin 2, Pbp1, suppresses TDP-43 toxicity in yeast (Elden et al. 2010). Moreover, reduced expression of Ataxin 2 in *Drosophila* mitigates TDP-43 toxicity (Elden et al. 2010). Polyglutamine expansions (>34 Qs) in Ataxin 2 cause the neurodegenerative disease spinocerebellar ataxia type 2 (Imbert et al. 1996; Pulst et al. 1996; Lorenzetti et al. 1997). Remarkably, intermediate polyglutamine expansions (27–33 glutamines) in Ataxin 2 are a common genetic risk factor for ALS (Elden et al. 2010; Bonini and Gitler 2011; Lee et al. 2011a,b; Yu et al. 2011; Gispert et al. 2012; Hart and Gitler 2012; Hart et al. 2012). Small-molecule inhibitors of Ataxin 2 could be valuable, but the precise functions of Pbp1 and Ataxin 2 are not completely understood, although Pbp1 interacts with Pab1 and regulates mRNA polyadenylation and stress-granule biogenesis (Mangus et al. 1998). Another strategy would be to reduce Ataxin 2 expression via siRNA or antisense technology. Encouragingly, Ataxin 2 deletion in mice is not lethal and is associated with mild obesity phenotypes (Kiehl et al. 2006; Lastres-Becker et al. 2008), which augurs well for this potential approach.

TDP-43: Biology, Pathobiology, and Therapeutics

INHIBITING OR REDUCING EXPRESSION OF Dbr1

The lariat-debranching enzyme, Dbr1, has also emerged as a deletion suppressor of TDP-43 and FUS toxicity in yeast (Armakola et al. 2012). Dbr1 hydrolyzes 2'–5' prime branched phosphodiester bonds, which occur at the branch point of excised lariat intron RNA, converting them to linear RNA molecules that are then degraded (Chapman and Boeke 1991). When Dbr1 is deleted, intronic lariats accumulate and, surprisingly, co-localize with TDP-43 inclusions in the cytoplasm of yeast (Armakola et al. 2012). Thus, these accumulated intronic lariat RNAs may act as a decoy and engage TDP-43 to prevent the depletion or sequestration of essential cellular RNAs or RBPs (Armakola et al. 2012). Alternatively, lariat RNAs might engage TDP-43 and alter its misfolding pathway such that more benign TDP-43 structures accumulate. Importantly, depletion of Dbr1 from human neuronal cells or primary rat neurons also reduced TDP-43 toxicity (Armakola et al. 2012; Sun and Cleveland 2012). Thus, the effect of reduced Dbr1 levels on TDP-43 toxicity is conserved from yeast to mammals (Armakola et al. 2012). These advances suggest that small molecules that inhibit Dbr1 activity or antisense strategies to reduce Dbr1 expression could have therapeutic utility in TDP-43 and FUS proteinopathies (Figley and Gitler 2013).

TUNING eIF2 α PHOSPHORYLATION TO LIMIT STRESS-GRANULE ASSEMBLY

Stress granules are cytoplasmic RNP compartments where nontranslating mRNAs, as well as factors involved in translation repression and mRNA decay, are partitioned when translation is stalled or impeded in response to environmental stress (Anderson and Kedersha 2008; Li et al. 2013; Ramaswami et al. 2013). TDP-43 co-localizes with stress granules, and it has been proposed that prolonged stress-granule accumulation enables TDP-43 to access pathological conformers that cause neurodegeneration (Li et al. 2013; Ramaswami et al. 2013). Thus, agents that promote stress-granule disassembly

L. Guo and J. Shorter

or inhibit their initial assembly could have therapeutic potential (Li et al. 2013; Ramaswami et al. 2013). Indeed, several genetic modifiers of TDP-43 and FUS toxicity in yeast are involved in stress-granule assembly pathways (Sun et al. 2011; Kim et al. 2014). Interestingly, phosphorylation of the translation initiation factor, eukaryotic translation initiation factor 2 (eIF2 α), decreases protein synthesis and induces stress-granule formation (Thomas et al. 2011). Inhibition of PERK (protein kinase RNA-like endoplasmic reticulum kinase), a critical effector of unfolded protein response, by the small-molecule GSK2606414 reduces eIF2 α phosphorylation (Axten et al. 2012, 2013; Kim et al. 2014). Remarkably, GSK2606414 mitigates TDP-43 toxicity in *Drosophila* and mammalian neurons, presumably by restoring protein synthesis and thereby antagonizing stress-granule formation (Kim et al. 2014). Moreover, orally administered GSK2606414 is profoundly neuroprotective and prevents clinical disease in prion-infected mice, as do other strategies to reduce eIF2 α phosphorylation (Moreno et al. 2012, 2013). Unfortunately, however, GSK2606414 also causes weight loss and mild hyperglycemia, which is likely a result of an inhibition of PERK that is too severe in the pancreas (Harding et al. 2001; Moreno et al. 2013). Thus, alternative strategies to pharmacologically modulate translational inhibition caused by phosphorylated eIF2 α could be opportune. Interestingly, the small molecule *N,N'*-trans-(cyclohexane-1,4-diyl)-bis-(2-(4-chlorophenoxy)acetamide) (ISRIB) prevents translational inhibition downstream from eIF2 α phosphorylation (Sidrauski et al. 2013). Remarkably, ISRIB conferred neuroprotection in prion-diseased mice without pancreatic toxicity (Halliday et al. 2015). Moreover, ISRIB induces the rapid dissolution of preformed stress granules, thereby releasing sequestered mRNAs for translation (Sidrauski et al. 2015). It will be of great interest to determine whether ISRIB also counters TDP-43 toxicity. Finally, tuning eIF2 α phosphorylation to cytoprotective rather than cytotoxic levels via inhibition of specific regulatory subunits of protein phosphatases (e.g., using guanabenz and Sephin1) has also yielded promising results in restoring protein homeo-

stasis and preventing neurodegeneration (Tsytler et al. 2011; Vaccaro et al. 2013; Das et al. 2015), and should be explored further in TDP-43 proteinopathy models.

ENGINEERED PROTEIN DISAGGREGASES TO REACTIVATE MISFOLDED TDP-43

Another promising therapeutic strategy is to uncover agents that reverse TDP-43 misfolding and restore TDP-43 to native structure and function (Shorter 2008, 2016; Jackrel and Shorter 2015). Such agents would contemporaneously eliminate any deleterious loss of function or toxic gain of function caused by misfolded TDP-43 (Jackrel and Shorter 2015). Moreover, any self-templating TDP-43 conformers that might spread pathology and any intrinsically toxic oligomeric forms of TDP-43 would also be cleared (Jackrel and Shorter 2015). We have engineered potentiated variants of Hsp104, an AAA⁺ ATPase and protein disaggregase from yeast, by introducing single missense mutations into the autoinhibitory middle domain (Jackrel and Shorter 2015). These potentiated Hsp104 variants solubilize preformed TDP-43 fibrils in vitro and suppress toxicity of TDP-43 and ALS-linked variants in yeast (Jackrel and Shorter 2014a,b, 2015; Jackrel et al. 2014a,b; Sweeny et al. 2015; Torrente et al. 2016). Remarkably, potentiated Hsp104 variants also eliminate TDP-43 inclusions and restore nuclear TDP-43 localization in yeast, phenotypes that could be transformative if they were achieved in ALS patients (Jackrel and Shorter 2014a, 2015; Jackrel et al. 2014a). The challenge ahead is to apply engineered Hsp104 variants to neuronal and animal models of TDP-43 proteinopathies (Jackrel and Shorter 2015).

Hsp104 is absent in metazoa (Shorter 2008; Erives and Fassler 2015). Thus, it is also imperative to uncover human protein disaggregases that might also reverse TDP-43 aggregation and restore TDP-43 to the nucleus. Here, two systems are of particular interest. First, Hsp110, Hsp70, Hsp40, and the small heat shock proteins collaborate to dissolve and reactivate proteins trapped in disordered aggregates (Shorter

2011; Duennwald et al. 2012; Rampelt et al. 2012; Mattoo et al. 2013; Torrente and Shorter 2013; Nillegoda et al. 2015). Hsp110, Hsp70, and Hsp40 can also depolymerize preformed amyloid fibrils (Duennwald et al. 2012; Gao et al. 2015). Moreover, Hsp110, Hsp70, and Hsp40 are important for the resolution of stress granules after stress (Cherkasov et al. 2013; Kroschwald et al. 2015; Walters et al. 2015; Jain et al. 2016). Second, the highly conserved AAA⁺ ATPase, VCP, not only can drive clearance of stress granules via autophagy but also can potentially release soluble proteins in the process (Buchan et al. 2013; Ramaswami et al. 2013). Intriguingly, VCP mutations are a cause of ALS (Johnson et al. 2010; Shaw 2010), and ALS-linked VCP variants show defects in stress-granule clearance and perturb TDP-43 proteostasis (Ritson et al. 2010; Buchan et al. 2013; Ramaswami et al. 2013). It will be important to determine whether the Hsp110 system or the VCP system can counter TDP-43 aggregation and toxicity. Moreover, based on earlier studies on Hsp104 (Jackrel and Shorter 2015), it might also be possible to engineer the Hsp110 or VCP system to more effectively reverse TDP-43 misfolding. Finally, it will also be of great interest to uncover small-molecule activators that enhance the disaggregase activity of the Hsp110 system or the stress-granule clearance activity of VCP (Shorter 2016). In this way, we may directly reverse the TDP-43 misfolding events that underpin diverse neurodegenerative disorders.

OUTLOOK

Although there continue to be no effective therapeutics for ALS or other TDP-43 proteinopathies, it is clear that the past several years have yielded a transformative change in our understanding of these diseases and their underlying mechanisms. To develop innovative therapies and uncover novel targets, we need to more fully understand the complexity of TDP-43's structure, function, biology, misfolding, and pathogenesis. This endeavor will require a major focused effort in basic research before translation to the clinic. Moreover, we suggest that thera-

TDP-43: Biology, Pathobiology, and Therapeutics

pies able to combine some of the approaches outlined above could yield synergistic advances similar to combination therapies that have been successfully deployed to restore proteostasis, eliminate yeast prions, and combat cystic fibrosis and HIV (Clavel and Hance 2004; Mu et al. 2008; Roberts et al. 2009; Duennwald and Shorter 2010; Shorter 2010; Wainwright et al. 2015).

ACKNOWLEDGMENTS

We thank Alice Ford for helpful comments on the manuscript. We are very grateful for support from a Glenn/AFAR Postdoctoral Fellowship for Translational Research on Aging grant from the Lawrence Ellison Foundation (L.G.), National Institutes of Health grants R21NS067354 and R01GM099836, a Muscular Dystrophy Association Research Award (MDA277268), an ALSA Investigator Initiated Award, the Life Extension Foundation, a Linda Pechenik Montague Research Award, the Packard Center for ALS Research at Johns Hopkins University, and Target ALS (J.S.).

REFERENCES

*Reference is also in this collection.

- Acharya KK, Govind CK, Shore AN, Stoler MH, Reddi PP. 2006. *cis*-Requirement for the maintenance of round spermatid-specific transcription. *Dev Biol* **295**: 781–790.
- Alami NH, Smith RB, Carrasco MA, Williams LA, Winborn CS, Han SS, Kiskinis E, Winborn B, Freibaum BD, Kana-garaj A, et al. 2014. Axonal transport of TDP-43 mRNA granules is impaired by ALS-causing mutations. *Neuron* **81**: 536–543.
- Alberti S, Halfmann R, King O, Kapila A, Lindquist S. 2009. A systematic survey identifies prions and illuminates sequence features of prionogenic proteins. *Cell* **137**: 146–158.
- Amador-Ortiz C, Lin WL, Ahmed Z, Personett D, Davies P, Duara R, Graff-Radford NR, Hutton ML, Dickson DW. 2007. TDP-43 immunoreactivity in hippocampal sclerosis and Alzheimer's disease. *Ann Neurol* **61**: 435–445.
- Anderson P, Kedersha N. 2008. Stress granules: The Tao of RNA triage. *Trends Biochem Sci* **33**: 141–150.
- Arai T, Hasegawa M, Akiyama H, Ikeda K, Nonaka T, Mori H, Mann D, Tsuchiya K, Yoshida M, Hashizume Y, et al. 2006. TDP-43 is a component of ubiquitin-positive tau-negative inclusions in frontotemporal lobar degeneration and amyotrophic lateral sclerosis. *Biochem Biophys Res Commun* **351**: 602–611.

L. Guo and J. Shorter

- Armakola M, Higgins MJ, Figley MD, Barmada SJ, Scarborough EA, Diaz Z, Fang X, Shorter J, Krogan NJ, Finkbeiner S, et al. 2012. Inhibition of RNA lariat debranching enzyme suppresses TDP-43 toxicity in ALS disease models. *Nat Genet* **44**: 1302–1309.
- Ash PE, Zhang YJ, Roberts CM, Saldi T, Hutter H, Buratti E, Petrucelli L, Link CD. 2010. Neurotoxic effects of TDP-43 overexpression in *C. elegans*. *Hum Mol Genet* **19**: 3206–3218.
- Avendano-Vazquez SE, Dhir A, Bembich S, Buratti E, Proudfoot N, Baralle FE. 2012. Autoregulation of TDP-43 mRNA levels involves interplay between transcription, splicing, and alternative polyA site selection. *Genes Dev* **26**: 1679–1684.
- Axten JM, Medina JR, Feng Y, Shu A, Romeril SP, Grant SW, Li WH, Heering DA, Minthorn E, Mencken T, et al. 2012. Discovery of 7-methyl-5-(1-([3-(trifluoromethyl)phenyl]acetyl)-2,3-dihydro-1H-indol-5-yl)-7H-pyrrolo[2,3-d]pyrimidin-4-amine (GSK2606414), a potent and selective first-in-class inhibitor of protein kinase R (PKR)-like endoplasmic reticulum kinase (PERK). *J Med Chem* **55**: 7193–7207.
- Axten JM, Romeril SP, Shu A, Ralph J, Medina JR, Feng Y, Li WH, Grant SW, Heering DA, Minthorn E, et al. 2013. Discovery of GSK2656157: An optimized PERK inhibitor selected for preclinical development. *ACS Med Chem Lett* **4**: 964–968.
- Ayala YM, Pantano S, D'Ambrogio A, Buratti E, Brindisi A, Marchetti C, Romano M, Baralle FE. 2005. Human, *Drosophila*, and *C. elegans* TDP43: Nucleic acid binding properties and splicing regulatory function. *J Mol Biol* **348**: 575–588.
- Ayala YM, Pagani F, Baralle FE. 2006. TDP43 depletion rescues aberrant CFTR exon 9 skipping. *FEBS Lett* **580**: 1339–1344.
- Ayala YM, Zago P, D'Ambrogio A, Xu YF, Petrucelli L, Buratti E, Baralle FE. 2008. Structural determinants of the cellular localization and shuttling of TDP-43. *J Cell Sci* **121**: 3778–3785.
- Ayala YM, De Conti L, Avendano-Vazquez SE, Dhir A, Romano M, D'Ambrogio A, Tollervey J, Ule J, Baralle M, Buratti E, et al. 2011. TDP-43 regulates its mRNA levels through a negative feedback loop. *EMBO J* **30**: 277–288.
- Barmada SJ, Skibinski G, Korb E, Rao EJ, Wu JY, Finkbeiner S. 2010. Cytoplasmic mislocalization of TDP-43 is toxic to neurons and enhanced by a mutation associated with familial amyotrophic lateral sclerosis. *J Neurosci* **30**: 639–649.
- Barmada SJ, Serio A, Arjun A, Bilican B, Daub A, Ando DM, Tsvetkov A, Pleiss M, Li X, Peisach D, et al. 2014. Autophagy induction enhances TDP43 turnover and survival in neuronal ALS models. *Nat Chem Biol* **10**: 677–685.
- Benatar M, Wu J, Fernandez C, Weihl CC, Katzen H, Steele J, Oskarsson B, Taylor JP. 2013. Motor neuron involvement in multisystem proteinopathy: Implications for ALS. *Neurology* **80**: 1874–1880.
- Bensimon G, Lacomblez L, Meininger V. 1994. A controlled trial of riluzole in amyotrophic lateral sclerosis. ALS/Riluzole Study Group. *N Engl J Med* **330**: 585–591.
- Bentmann E, Neumann M, Tahirovic S, Rodde R, Dormann D, Haass C. 2012. Requirements for stress granule recruitment of fused in sarcoma (FUS) and TAR DNA-binding protein of 43 kDa (TDP-43). *J Biol Chem* **287**: 23079–23094.
- Berchowitz LE, Kabachinski G, Walker MR, Carlile TM, Gilbert WV, Schwartz TU, Amon A. 2015. Regulated formation of an amyloid-like translational repressor governs gametogenesis. *Cell* **163**: 406–418.
- Bonini NM, Gitler AD. 2011. Model organisms reveal insight into human neurodegenerative disease: Ataxin-2 intermediate-length polyglutamine expansions are a risk factor for ALS. *J Mol Neurosci* **45**: 676–683.
- Brettschneider J, Del Tredici K, Toledo JB, Robinson JL, Irwin DJ, Grossman M, Suh E, Van Deerlin VM, Wood EM, Baek Y, et al. 2013. Stages of pTDP-43 pathology in amyotrophic lateral sclerosis. *Ann Neurol* **74**: 20–38.
- Brettschneider J, Arai K, Del Tredici K, Toledo JB, Robinson JL, Lee EB, Kuwabara S, Shibuya K, Irwin DJ, Fang L, et al. 2014. TDP-43 pathology and neuronal loss in amyotrophic lateral sclerosis spinal cord. *Acta Neuropathol* **128**: 423–437.
- Buchan JR, Kolaitis RM, Taylor JP, Parker R. 2013. Eukaryotic stress granules are cleared by autophagy and Cdc48/VCP function. *Cell* **153**: 1461–1474.
- Budini M, Romano V, Quadri Z, Buratti E, Baralle FE. 2015. TDP-43 loss of cellular function through aggregation requires additional structural determinants beyond its C-terminal Q/N prion-like domain. *Hum Mol Genet* **24**: 9–20.
- Bulawa CE, Connelly S, Devit M, Wang L, Weigel C, Fleming JA, Packman J, Powers ET, Wiseman RL, Foss TR, et al. 2012. Tafamidis, a potent and selective transthyretin kinetic stabilizer that inhibits the amyloid cascade. *Proc Natl Acad Sci* **109**: 9629–9634.
- Buratti E, Baralle FE. 2001. Characterization and functional implications of the RNA binding properties of nuclear factor TDP-43, a novel splicing regulator of CFTR exon 9. *J Biol Chem* **276**: 36337–36343.
- Buratti E, Brindisi A, Pagani F, Baralle FE. 2004. Nuclear factor TDP-43 binds to the polymorphic TG repeats in CFTR intron 8 and causes skipping of exon 9: A functional link with disease penetrance. *Am J Hum Genet* **74**: 1322–1325.
- Buratti E, Brindisi A, Giombi M, Tisminetzky S, Ayala YM, Baralle FE. 2005. TDP-43 binds heterogeneous nuclear ribonucleoprotein A/B through its C-terminal tail: An important region for the inhibition of cystic fibrosis transmembrane conductance regulator exon 9 splicing. *J Biol Chem* **280**: 37572–37584.
- Caccamo A, Majumder S, Oddo S. 2012. Cognitive decline typical of frontotemporal lobar degeneration in transgenic mice expressing the 25-kDa C-terminal fragment of TDP-43. *Am J Pathol* **180**: 293–302.
- Chapman KB, Boeke JD. 1991. Isolation and characterization of the gene encoding yeast debranching enzyme. *Cell* **65**: 483–492.
- Chen AK, Lin RY, Hsieh EZ, Tu PH, Chen RP, Liao TY, Chen W, Wang CH, Huang JJ. 2010. Induction of amyloid fibrils by the C-terminal fragments of TDP-43 in amyotrophic lateral sclerosis. *J Am Chem Soc* **132**: 1186–1187.
- Chen-Plotkin AS, Lee VM, Trojanowski JQ. 2010. TAR DNA-binding protein 43 in neurodegenerative disease. *Nat Rev Neurol* **6**: 211–220.

- Cherkasov V, Hofmann S, Druffel-Augustin S, Mogk A, Tyedmers J, Stoecklin G, Bukau B. 2013. Coordination of translational control and protein homeostasis during severe heat stress. *Curr Biol* **23**: 2452–2462.
- Chiang PM, Ling J, Jeong YH, Price DL, Aja SM, Wong PC. 2010. Deletion of TDP-43 down-regulates Tbc1d1, a gene linked to obesity, and alters body fat metabolism. *Proc Natl Acad Sci* **107**: 16320–16324.
- Clavel F, Hance AJ. 2004. HIV drug resistance. *N Engl J Med* **350**: 1023–1035.
- Cohen TJ, Hwang AW, Restrepo CR, Yuan CX, Trojanowski JQ, Lee VM. 2015. An acetylation switch controls TDP-43 function and aggregation propensity. *Nat Commun* **6**: 5845.
- Colby DW, Giles K, Legname G, Wille H, Baskakov IV, DeArmond SJ, Prusiner SB. 2009. Design and construction of diverse mammalian prion strains. *Proc Natl Acad Sci* **106**: 20417–20422.
- Conicella AE, Zerze GH, Mittal J, Fawzi NL. 2016. ALS mutations disrupt phase separation mediated by α -helical structure in the TDP-43 low-complexity C-terminal domain. *Structure* **24**: 1537–1549.
- Couthouis J, Hart MP, Shorter J, DeJesus-Hernandez M, Erion R, Oristano R, Liu AX, Ramos D, Jethava N, Hosangadi D, et al. 2011. A yeast functional screen predicts new candidate ALS disease genes. *Proc Natl Acad Sci* **108**: 20881–20890.
- Couthouis J, Hart MP, Erion R, King OD, Diaz Z, Nakaya T, Ibrahim F, Kim HJ, Mojsilovic-Petrovic J, Panossian S, et al. 2012. Evaluating the role of the FUS/TLS-related gene EWSR1 in amyotrophic lateral sclerosis. *Hum Mol Genet* **21**: 2899–2911.
- Couthouis J, Raphael AR, Daneshjou R, Gitler AD. 2014. Targeted exon capture and sequencing in sporadic amyotrophic lateral sclerosis. *PLoS Genet* **10**: e1004704.
- Coyne AN, Siddegowda BB, Estes PS, Johannesmeyer J, Kovalik T, Daniel SG, Pearson A, Bowser R, Zarnescu DC. 2014. Futsch/MAP1B mRNA is a translational target of TDP-43 and is neuroprotective in a *Drosophila* model of amyotrophic lateral sclerosis. *J Neurosci* **34**: 15962–15974.
- Cushman M, Johnson BS, King OD, Gitler AD, Shorter J. 2010. Prion-like disorders: Blurring the divide between transmissibility and infectivity. *J Cell Sci* **123**: 1191–1201.
- Da Cruz S, Cleveland DW. 2011. Understanding the role of TDP-43 and FUS/TLS in ALS and beyond. *Curr Opin Neurobiol* **21**: 904–919.
- D'Ambrogio A, Buratti E, Stuani C, Guarnaccia C, Romano M, Ayala YM, Baralle FE. 2009. Functional mapping of the interaction between TDP-43 and hnRNP A2 in vivo. *Nucleic Acids Res* **37**: 4116–4126.
- Das I, Krzyzosiak A, Schneider K, Wrabetz L, D'Antonio M, Barry N, Sigurdardottir A, Bertolotti A. 2015. Preventing proteostasis diseases by selective inhibition of a phosphatase regulatory subunit. *Science* **348**: 239–242.
- Davidson Y, Kelley T, Mackenzie IR, Pickering-Brown S, Du Plessis D, Neary D, Snowden JS, Mann DM. 2007. Ubiquitinated pathological lesions in frontotemporal lobar degeneration contain the TAR DNA-binding protein, TDP-43. *Acta Neuropathol* **113**: 521–533.
- DeJesus-Hernandez M, Mackenzie IR, Boeve BF, Boxer AL, Baker M, Rutherford NJ, Nicholson AM, Finch NA, Flynn H, Adamson J, et al. 2011. Expanded GGGGCC hexanucleotide repeat in noncoding region of C9ORF72 causes chromosome 9p-linked FTD and ALS. *Neuron* **72**: 245–256.
- Deleault NR, Lucassen RW, Supattapone S. 2003. RNA molecules stimulate prion protein conversion. *Nature* **425**: 717–720.
- Deng HX, Zhai H, Bigio EH, Yan J, Fecto F, Ajroud K, Mishra M, Ajroud-Driss S, Heller S, Sufit R, et al. 2010. FUS-immunoreactive inclusions are a common feature in sporadic and non-SOD1 familial amyotrophic lateral sclerosis. *Ann Neurol* **67**: 739–748.
- Deng HX, Chen W, Hong ST, Boycott KM, Gorrie GH, Siddique N, Yang Y, Fecto F, Shi Y, Zhai H, et al. 2011. Mutations in UBQLN2 cause dominant X-linked juvenile and adult-onset ALS and ALS/dementia. *Nature* **477**: 211–215.
- Driscaldi B, Colnaghi L, Fioriti L, Rao N, Myers C, Snyder AM, Metzger DJ, Tarasoff J, Konstantinov E, Fraser PE, et al. 2015. SUMOylation is an inhibitory constraint that regulates the prion-like aggregation and activity of CPEB3. *Cell Rep* **11**: 1694–1702.
- Duennwald ML, Shorter J. 2010. Countering amyloid polymorphism and drug resistance with minimal drug cocktails. *Prion* **4**: 244–251.
- Duennwald ML, Echeverria A, Shorter J. 2012. Small heat shock proteins potentiate amyloid dissolution by protein disaggregases from yeast and humans. *PLoS Biol* **10**: e1001346.
- Eisenberg D, Jucker M. 2012. The amyloid state of proteins in human diseases. *Cell* **148**: 1188–1203.
- Elden AC, Kim HJ, Hart MP, Chen-Plotkin AS, Johnson BS, Fang X, Armakola M, Geser F, Greene R, Lu MM, et al. 2010. Ataxin-2 intermediate-length polyglutamine expansions are associated with increased risk for ALS. *Nature* **466**: 1069–1075.
- Erives AJ, Fassler JS. 2015. Metabolic and chaperone gene loss marks the origin of animals: Evidence for Hsp104 and Hsp78 chaperones sharing mitochondrial enzymes as clients. *PLoS ONE* **10**: e0117192.
- Estes PS, Boehringer A, Zwick R, Tang JE, Grigsby B, Zarnescu DC. 2011. Wild-type and A315T mutant TDP-43 exert differential neurotoxicity in a *Drosophila* model of ALS. *Hum Mol Genet* **20**: 2308–2321.
- Fang YS, Tsai KJ, Chang YJ, Kao P, Woods R, Kuo PH, Wu CC, Liao JY, Chou SC, Lin V, et al. 2014. Full-length TDP-43 forms toxic amyloid oligomers that are present in frontotemporal lobar dementia-TDP patients. *Nat Commun* **5**: 4824.
- Feiguin F, Godena VK, Romano G, D'Ambrogio A, Klima R, Baralle FE. 2009. Depletion of TDP-43 affects *Drosophila* motoneurons terminal synapses and locomotive behavior. *FEBS Lett* **583**: 1586–1592.
- Feiler MS, Strobel B, Freischmidt A, Hefnerich AM, Kappel J, Brewer BM, Li D, Thal DR, Walther P, Ludolph AC, et al. 2015. TDP-43 is intercellularly transmitted across axon terminals. *J Cell Biol* **211**: 897–911.
- Fiesel FC, Weber SS, Supper J, Zell A, Kahle PJ. 2012. TDP-43 regulates global translational yield by splicing of exon

L. Guo and J. Shorter

- junction complex component SKAR. *Nucleic Acids Res* **40**: 2668–2682.
- Figley MD, Gitler AD. 2013. Yeast genetic screen reveals novel therapeutic strategy for ALS. *Rare Dis* **1**: e24420.
- Fioriti L, Myers C, Huang YY, Li X, Stephan JS, Trifilieff P, Colnaghi L, Kosmidis S, Drisaldi B, Pavlopoulos E, et al. 2015. The persistence of hippocampal-based memory requires protein synthesis mediated by the prion-like protein CPEB3. *Neuron* **86**: 1433–1448.
- Ford AF, Shorter J. 2015. Fleeting amyloid-like forms of Rim4 ensure meiotic fidelity. *Cell* **163**: 275–276.
- Fox BW, Tibbetts RS. 2015. Neurodegeneration: Problems at the nuclear pore. *Nature* **525**: 36–37.
- Freibaum BD, Chitta RK, High AA, Taylor JP. 2010. Global analysis of TDP-43 interacting proteins reveals strong association with RNA splicing and translation machinery. *J Proteome Res* **9**: 1104–1120.
- Freibaum BD, Lu Y, Lopez-Gonzalez R, Kim NC, Almeida S, Lee KH, Badders N, Valentine M, Miller BL, Wong PC, et al. 2015. GGGGCC repeat expansion in C9orf72 compromises nucleocytoplasmic transport. *Nature* **525**: 129–133.
- Fuentealba RA, Udan M, Bell S, Wegorzewska I, Shao J, Diamond MI, Weihl CC, Baloh RH. 2010. Interaction with polyglutamine aggregates reveals a Q/N-rich domain in TDP-43. *J Biol Chem* **285**: 26304–26314.
- Fujita Y, Fujita S, Takatama M, Ikeda M, Okamoto K. 2011. Numerous FUS-positive inclusions in an elderly woman with motor neuron disease. *Neuropathology* **31**: 170–176.
- Furukawa Y, Kaneko K, Watanabe S, Yamanaka K, Nukina N. 2011. A seeding reaction recapitulates intracellular formation of Sarkosyl-insoluble transactivation response element (TAR) DNA-binding protein-43 inclusions. *J Biol Chem* **286**: 18664–18672.
- Gao X, Carroni M, Nussbaum-Krammer C, Mogk A, Nille-goda NB, Szlachet A, Guilbride DL, Saibil HR, Mayer MP, Bukau B. 2015. Human Hsp70 disaggregase reverses parkinson's-linked α -synuclein amyloid fibrils. *Mol Cell* **59**: 781–793.
- Geser F, Martinez-Lage M, Robinson J, Uryu K, Neumann M, Brandmeir NJ, Xie SX, Kwong LK, Elman L, McCluskey L, et al. 2009. Clinical and pathological continuum of multisystem TDP-43 proteinopathies. *Arch Neurol* **66**: 180–189.
- Gispert S, Kurz A, Waibel S, Bauer P, Liepelt I, Geisen C, Gitler AD, Becker T, Weber M, Berg D, et al. 2012. The modulation of amyotrophic lateral sclerosis risk by ataxin-2 intermediate polyglutamine expansions is a specific effect. *Neurobiol Dis* **45**: 356–361.
- Gitcho MA, Baloh RH, Chakraverty S, Mayo K, Norton JB, Levitch D, Hatanpaa KJ, White CL III, Bigio EH, Caselli R, et al. 2008. TDP-43 A315T mutation in familial motor neuron disease. *Ann Neurol* **63**: 535–538.
- Gitcho MA, Bigio EH, Mishra M, Johnson N, Weintraub S, Mesulam M, Rademakers R, Chakraverty S, Cruchaga C, Morris JC, et al. 2009. TARDBP 3'-UTR variant in autopsy-confirmed frontotemporal lobar degeneration with TDP-43 proteinopathy. *Acta Neuropathol* **118**: 633–645.
- Gitler AD, Shorter J. 2011. RNA-binding proteins with prion-like domains in ALS and FTL-D. *Prion* **5**: 179–187.
- Goldschmidt L, Teng PK, Riek R, Eisenberg D. 2010. Identifying the amyloids, proteins capable of forming amyloid-like fibrils. *Proc Natl Acad Sci* **107**: 3487–3492.
- Grabbe C, Dikic I. 2009. Functional roles of ubiquitin-like domain (ULD) and ubiquitin-binding domain (UBD) containing proteins. *Chem Rev* **109**: 1481–1494.
- Grad LI, Fernando SM, Cashman NR. 2015. From molecule to molecule and cell to cell: Prion-like mechanisms in amyotrophic lateral sclerosis. *Neurobiol Dis* **77**: 257–265.
- Gros-Louis F, Gaspar C, Rouleau GA. 2006. Genetics of familial and sporadic amyotrophic lateral sclerosis. *Biochim Biophys Acta* **1762**: 956–972.
- Guo L, Shorter J. 2015. It's raining liquids: RNA tunes viscoelasticity and dynamics of membraneless organelles. *Mol Cell* **60**: 189–192.
- Guo W, Chen Y, Zhou X, Kar A, Ray P, Chen X, Rao EJ, Yang M, Ye H, Zhu L, et al. 2011. An ALS-associated mutation affecting TDP-43 enhances protein aggregation, fibril formation and neurotoxicity. *Nat Struct Mol Biol* **18**: 822–830.
- Haines JD, Herbin O, de la Hera B, Vidaurre OG, Moy GA, Sun Q, Fung HY, Albrecht S, Alexandropoulos K, McCauley D, et al. 2015. Nuclear export inhibitors avert progression in preclinical models of inflammatory demyelination. *Nat Neurosci* **18**: 511–520.
- Halfmann R, Jarosz DE, Jones SK, Chang A, Lancaster AK, Lindquist S. 2012. Prions are a common mechanism for phenotypic inheritance in wild yeasts. *Nature* **482**: 363–368.
- Halliday M, Radford H, Sekine Y, Moreno J, Verity N, le Quesne J, Ortori CA, Barrett DA, Fromont C, Fischer PM, et al. 2015. Partial restoration of protein synthesis rates by the small molecule ISRIB prevents neurodegeneration without pancreatic toxicity. *Cell Death Dis* **6**: e1672.
- Hammarstrom P, Wiseman RL, Powers ET, Kelly JW. 2003. Prevention of transthyretin amyloid disease by changing protein misfolding energetics. *Science* **299**: 713–716.
- Han TW, Kato M, Xie S, Wu LC, Mirzaei H, Pei J, Chen M, Xie Y, Allen J, Xiao G, et al. 2012. Cell-free formation of RNA granules: Bound RNAs identify features and components of cellular assemblies. *Cell* **149**: 768–779.
- Hanson KA, Kim SH, Wassarman DA, Tibbetts RS. 2010. Ubiquitin modifies TDP-43 toxicity in a *Drosophila* model of amyotrophic lateral sclerosis (ALS). *J Biol Chem* **285**: 11068–11072.
- Harding HP, Zeng H, Zhang Y, Jungries R, Chung P, Plesken H, Sabatini DD, Ron D. 2001. Diabetes mellitus and exocrine pancreatic dysfunction in perk^{-/-} mice reveals a role for translational control in secretory cell survival. *Mol Cell* **7**: 1153–1163.
- Hart MP, Gitler AD. 2012. ALS-associated ataxin 2 polyQ expansions enhance stress-induced caspase 3 activation and increase TDP-43 pathological modifications. *J Neurosci* **32**: 9133–9142.
- Hart MP, Brettschneider J, Lee VM, Trojanowski JQ, Gitler AD. 2012. Distinct TDP-43 pathology in ALS patients with ataxin 2 intermediate-length polyQ expansions. *Acta Neuropathol* **124**: 221–230.
- Hewitt C, Kirby J, Highley JR, Hartley JA, Hibberd R, Hollinger HC, Williams TL, Ince PG, McDermott CJ, Shaw

- PJ. 2010. Novel FUS/TLS mutations and pathology in familial and sporadic amyotrophic lateral sclerosis. *Arch Neurol* **67**: 455–461.
- Huang YC, Lin KF, He RY, Tu PH, Koubek J, Hsu YC, Huang JJ. 2013. Inhibition of TDP-43 aggregation by nucleic acid binding. *PLoS ONE* **8**: e64002.
- Hurshman AR, White JT, Powers ET, Kelly JW. 2004. Trans-thyretin aggregation under partially denaturing conditions is a downhill polymerization. *Biochemistry* **43**: 7365–7381.
- Igaz LM, Kwong LK, Lee EB, Chen-Plotkin A, Swanson E, Unger T, Malunda J, Xu Y, Winton MJ, Trojanowski JQ, et al. 2011. Dysregulation of the ALS-associated gene TDP-43 leads to neuronal death and degeneration in mice. *J Clin Invest* **121**: 726–738.
- Iguchi Y, Katsuno M, Niwa J, Takagi S, Ishigaki S, Ikenaka K, Kawai K, Watanabe H, Yamanaka K, Takahashi R, et al. 2013. Loss of TDP-43 causes age-dependent progressive motor neuron degeneration. *Brain* **136**: 1371–1382.
- Imbert G, Saudou F, Yvert G, Devys D, Trotter Y, Garnier JM, Weber C, Mandel JL, Cancel G, Abbas N, et al. 1996. Cloning of the gene for spinocerebellar ataxia 2 reveals a locus with high sensitivity to expanded CAG/glutamine repeats. *Nat Genet* **14**: 285–291.
- Irwin DJ, Cairns NJ, Grossman M, McMillan CT, Lee EB, Van Deerlin VM, Lee VM, Trojanowski JQ. 2015. Frontotemporal lobar degeneration: Defining phenotypic diversity through personalized medicine. *Acta Neuropathol* **129**: 469–491.
- Jablonski MR, Markandiah SS, Jacob D, Meng NJ, Li K, Gennaro V, Lepore AC, Trotti D, Pasinelli P. 2014. Inhibiting drug efflux transporters improves efficacy of ALS therapeutics. *Ann Clin Transl Neurol* **1**: 996–1005.
- Jackrel ME, Shorter J. 2014a. Potentiated Hsp104 variants suppress toxicity of diverse neurodegenerative disease-linked proteins. *Dis Model Mech* **7**: 1175–1184.
- Jackrel ME, Shorter J. 2014b. Reversing deleterious protein aggregation with re-engineered protein disaggregases. *Cell Cycle* **13**: 1379–1383.
- Jackrel ME, Shorter J. 2015. Engineering enhanced protein disaggregases for neurodegenerative disease. *Prion* **9**: 90–109.
- Jackrel ME, DeSantis ME, Martinez BA, Castellano LM, Stewart RM, Caldwell KA, Caldwell GA, Shorter J. 2014a. Potentiated Hsp104 variants antagonize diverse proteotoxic misfolding events. *Cell* **156**: 170–182.
- Jackrel ME, Tariq A, Yee K, Weitzman R, Shorter J. 2014b. Isolating potentiated Hsp104 variants using yeast proteinopathy models. *J Vis Exp* **93**: e52089.
- Jain S, Wheeler JR, Walters RW, Agrawal A, Barsic A, Parker R. 2016. ATPase-modulated stress granules contain a diverse proteome and substructure. *Cell* **164**: 487–498.
- Johnson BS, McCaffery JM, Lindquist S, Gitler AD. 2008. A yeast TDP-43 proteinopathy model: Exploring the molecular determinants of TDP-43 aggregation and cellular toxicity. *Proc Natl Acad Sci* **105**: 6439–6444.
- Johnson BS, Snead D, Lee JJ, McCaffery JM, Shorter J, Gitler AD. 2009. TDP-43 is intrinsically aggregation-prone, and amyotrophic lateral sclerosis-linked mutations accelerate aggregation and increase toxicity. *J Biol Chem* **284**: 20329–20339.
- Johnson JO, Mandrioli J, Benatar M, Abramzon Y, Van Deerlin VM, Trojanowski JQ, Gibbs JR, Brunetti M, Gronka S, Wu J, et al. 2010. Exome sequencing reveals VCP mutations as a cause of familial ALS. *Neuron* **68**: 857–864.
- Josephs KA, Murray ME, Whitwell JL, Parisi JE, Petrucelli L, Jack CR, Petersen RC, Dickson DW. 2014a. Staging TDP-43 pathology in Alzheimer's disease. *Acta Neuropathol* **127**: 441–450.
- Josephs KA, Whitwell JL, Weigand SD, Murray ME, Tosakulwong N, Liesinger AM, Petrucelli L, Senjem ML, Knopman DS, Boeve BF, et al. 2014b. TDP-43 is a key player in the clinical features associated with Alzheimer's disease. *Acta Neuropathol* **127**: 811–824.
- Josephs KA, Murray ME, Whitwell JL, Tosakulwong N, Weigand SD, Petrucelli L, Liesinger AM, Petersen RC, Parisi JE, Dickson DW. 2016. Updated TDP-43 in Alzheimer's disease staging scheme. *Acta Neuropathol* **131**: 571–585.
- Jovicic A, Gitler AD. 2014. TDP-43 in ALS: Stay on target . . . almost there. *Neuron* **81**: 463–465.
- Jovicic A, Mertens J, Boeynaems S, Bogaert E, Chai N, Yamada SB, Paul JW 3rd, Sun S, Herdy JR, Bieri G, et al. 2015. Modifiers of C9orf72 dipeptide repeat toxicity connect nucleocytoplasmic transport defects to FTD/ALS. *Nat Neurosci* **18**: 1226–1229.
- Jung Y, Dickson DW, Murray ME, Whitwell JL, Knopman DS, Boeve BF, Jack CR Jr, Parisi JE, Petersen RC, Josephs KA. 2014. TDP-43 in Alzheimer's disease is not associated with clinical FTLD or Parkinsonism. *J Neurol* **261**: 1344–1348.
- Kabashi E, Valdmanis PN, Dion P, Spiegelman D, McConkey BJ, Vande Velde C, Bouchard JB, Lacomblez L, Pochigaeva K, Salachas F, et al. 2008. TARDBP mutations in individuals with sporadic and familial amyotrophic lateral sclerosis. *Nat Genet* **40**: 572–574.
- Kabashi E, Lin L, Tradewell ML, Dion PA, Bercier V, Bourgoin P, Rochefort D, Bel Hadj S, Durham HD, Vande Velde C, et al. 2010. Gain and loss of function of ALS-related mutations of TARDBP (TDP-43) cause motor deficits in vivo. *Hum Mol Genet* **19**: 671–683.
- Kato M, Han TW, Xie S, Shi K, Du X, Wu LC, Mirzaei H, Goldsmith EJ, Longgood J, Pei J, et al. 2012. Cell-free formation of RNA granules: Low complexity sequence domains form dynamic fibers within hydrogels. *Cell* **149**: 753–767.
- Kawahara Y, Mieda-Sato A. 2012. TDP-43 promotes micro-RNA biogenesis as a component of the Drosha and Dicer complexes. *Proc Natl Acad Sci* **109**: 3347–3352.
- Kayed R, Head E, Thompson JL, McIntire TM, Milton SC, Cotman CW, Glabe CG. 2003. Common structure of soluble amyloid oligomers implies common mechanism of pathogenesis. *Science* **300**: 486–489.
- Khan MR, Li L, Perez-Sanchez C, Saraf A, Florens L, Slaughter BD, Unruh JR, Si K. 2015. Amyloidogenic oligomerization transforms *Drosophila* Orb2 from a translation repressor to an activator. *Cell* **163**: 1468–1483.
- Kiehl TR, Nechiporuk A, Figueroa KP, Keating MT, Huynh DP, Pulst SM. 2006. Generation and characterization of Sca2 (ataxin-2) knockout mice. *Biochem Biophys Res Commun* **339**: 17–24.
- Kim SH, Shanware NP, Bowler MJ, Tibbetts RS. 2010. Amyotrophic lateral sclerosis-associated proteins TDP-

TDP-43: Biology, Pathobiology, and Therapeutics

L. Guo and J. Shorter

- 43 and FUS/TLS function in a common biochemical complex to co-regulate HDAC6 mRNA. *J Biol Chem* **285**: 34097–34105.
- Kim HJ, Kim NC, Wang YD, Scarborough EA, Moore J, Diaz Z, MacLea KS, Freibaum B, Li S, Molliex A, et al. 2013. Mutations in prion-like domains in hnRNPA2B1 and hnRNPA1 cause multisystem proteinopathy and ALS. *Nature* **495**: 467–473.
- Kim HJ, Raphael AR, LaDow ES, McGurk L, Weber RA, Trojanowski JQ, Lee VM, Finkbeiner S, Gitler AD, Bonini NM. 2014. Therapeutic modulation of eIF2 α phosphorylation rescues TDP-43 toxicity in amyotrophic lateral sclerosis disease models. *Nat Genet* **46**: 152–160.
- King OD, Gitler AD, Shorter J. 2012. The tip of the iceberg: RNA-binding proteins with prion-like domains in neurodegenerative disease. *Brain Res* **1462**: 61–80.
- Kraemer BC, Schuck T, Wheeler JM, Robinson LC, Trojanowski JQ, Lee VM, Schellenberg GD. 2010. Loss of murine TDP-43 disrupts motor function and plays an essential role in embryogenesis. *Acta Neuropathol* **119**: 409–419.
- Kroschwald S, Maharana S, Mateju D, Malinowska L, Nuske E, Poser I, Richter D, Alberti S. 2015. Promiscuous interactions and protein disaggregases determine the material state of stress-inducible RNP granules. *eLife* **4**: e06807.
- Kuo PH, Chiang CH, Wang YT, Doudeva LG, Yuan HS. 2014. The crystal structure of TDP-43 RRM1-DNA complex reveals the specific recognition for UG- and TG-rich nucleic acids. *Nucleic Acids Res* **42**: 4712–4722.
- Kwiatkowski TJ Jr, Bosco DA, Leclerc AL, Tamrazian E, Vanderburg CR, Russ C, Davis A, Gilchrist J, Kasarskis EJ, Munsat T, et al. 2009. Mutations in the FUS/TLS gene on chromosome 16 cause familial amyotrophic lateral sclerosis. *Science* **323**: 1205–1208.
- Kwon I, Xiang S, Kato M, Wu L, Theodoropoulos P, Wang T, Kim J, Yun J, Xie Y, McKnight SL. 2014. Poly-dipeptides encoded by the C9orf72 repeats bind nucleoli, impede RNA biogenesis, and kill cells. *Science* **345**: 1139–1145.
- Kwong LK, Uryu K, Trojanowski JQ, Lee VM. 2008. TDP-43 proteinopathies: Neurodegenerative protein misfolding diseases without amyloidosis. *Neurosignals* **16**: 41–51.
- Lagier-Tourenne C, Cleveland DW. 2009. Rethinking ALS: The FUS about TDP-43. *Cell* **136**: 1001–1004.
- Lagier-Tourenne C, Polymenidou M, Cleveland DW. 2010. TDP-43 and FUS/TLS: Emerging roles in RNA processing and neurodegeneration. *Hum Mol Genet* **19**: R46–R64.
- Lagier-Tourenne C, Polymenidou M, Hutt KR, Vu AQ, Baughn M, Huelga SC, Clutario KM, Ling SC, Liang TY, Mazur C, et al. 2012. Divergent roles of ALS-linked proteins FUS/TLS and TDP-43 intersect in processing long pre-mRNAs. *Nat Neurosci* **15**: 1488–1497.
- Lalmansingh AS, Urekar CJ, Reddi PP. 2011. TDP-43 is a transcriptional repressor: The testis-specific mouse *acrvi* gene is a TDP-43 target in vivo. *J Biol Chem* **286**: 10970–10982.
- Lashuel HA, Hartley D, Petre BM, Walz T, Lansbury PT Jr. 2002. Neurodegenerative disease: Amyloid pores from pathogenic mutations. *Nature* **418**: 291.
- Lastres-Becker I, Brodesser S, Lutjohann D, Azizov M, Buchmann J, Hintermann E, Sandhoff K, Schurmann A, Noack J, Auburger G. 2008. Insulin receptor and lipid metabolism pathology in ataxin-2 knock-out mice. *Hum Mol Genet* **17**: 1465–1481.
- Lattante S, Rouleau GA, Kabashi E. 2013. TARDBP and FUS mutations associated with amyotrophic lateral sclerosis: Summary and update. *Hum Mutat* **34**: 812–826.
- Lee T, Li YR, Chesi A, Hart MP, Ramos D, Jethava N, Hosangadi D, Epstein J, Hodges B, Bonini NM, et al. 2011a. Evaluating the prevalence of polyglutamine repeat expansions in amyotrophic lateral sclerosis. *Neurology* **76**: 2062–2065.
- Lee T, Li YR, Ingre C, Weber M, Grehl T, Gredal O, de Carvalho M, Meyer T, Tysnes OB, Auburger G, et al. 2011b. Ataxin-2 intermediate-length polyglutamine expansions in European ALS patients. *Hum Mol Genet* **20**: 1697–1700.
- Lee EB, Lee VM, Trojanowski JQ. 2012. Gains or losses: Molecular mechanisms of TDP43-mediated neurodegeneration. *Nat Rev Neurosci* **13**: 38–50.
- Legname G, Baskakov IV, Nguyen HO, Riesner D, Cohen FE, DeArmond SJ, Prusiner SB. 2004. Synthetic mammalian prions. *Science* **305**: 673–676.
- Li Y, Ray P, Rao EJ, Shi C, Guo W, Chen X, Woodruff EA III, Fushimi K, Wu JY. 2010. A *Drosophila* model for TDP-43 proteinopathy. *Proc Natl Acad Sci* **107**: 3169–3174.
- Li YR, King OD, Shorter J, Gitler AD. 2013. Stress granules as crucibles of ALS pathogenesis. *J Cell Biol* **201**: 361–372.
- Lim L, Wei Y, Lu Y, Song J. 2016. ALS-causing mutations significantly perturb the self-assembly and interaction with nucleic acid of the intrinsically disordered prion-like domain of TDP-43. *PLoS Biol* **14**: e1002338.
- Lin Y, Protter DS, Rosen MK, Parker R. 2015. Formation and maturation of phase-separated liquid droplets by RNA-binding proteins. *Mol Cell* **60**: 208–219.
- Ling SC, Albuquerque CB, Han JS, Lagier-Tourenne C, Tokunaga S, Zhou H, Cleveland DW. 2010. ALS-associated mutations in TDP-43 increase its stability and promote TDP-43 complexes with FUS/TLS. *Proc Natl Acad Sci* **107**: 13318–13323.
- Ling SC, Polymenidou M, Cleveland DW. 2013. Converging mechanisms in ALS and FTD: Disrupted RNA and protein homeostasis. *Neuron* **79**: 416–438.
- Ling JB, Pletnikova O, Troncoso JC, Wong PC. 2015. TDP-43 repression of nonconserved cryptic exons is compromised in ALS-FTD. *Science* **349**: 650–655.
- Liu-Yesucevitz L, Bilgutay A, Zhang YJ, Vanderweyde T, Citro A, Mehta T, Zaarur N, McKee A, Bowser R, Sherman M, et al. 2010. Tar DNA binding protein-43 (TDP-43) associates with stress granules: Analysis of cultured cells and pathological brain tissue. *PLoS ONE* **5**: e13250.
- Liu-Yesucevitz L, Bassell GJ, Gitler AD, Hart AC, Klann E, Richter JD, Warren ST, Wolozin B. 2011. Local RNA translation at the synapse and in disease. *J Neurosci* **31**: 16086–16093.
- Liu-Yesucevitz L, Lin AY, Ebata A, Boon JY, Reid W, Xu YF, Kobrin K, Murphy GJ, Petrucelli L, Wolozin B. 2014. ALS-linked mutations enlarge TDP-43-enriched neuronal RNA granules in the dendritic arbor. *J Neurosci* **34**: 4167–4174.

TDP-43: Biology, Pathobiology, and Therapeutics

- Lorenzetti D, Bohlega S, Zoghbi HY. 1997. The expansion of the CAG repeat in ataxin-2 is a frequent cause of autosomal dominant spinocerebellar ataxia. *Neurology* **49**: 1009–1013.
- Lu Y, Ferris J, Gao FB. 2009. Frontotemporal dementia and amyotrophic lateral sclerosis-associated disease protein TDP-43 promotes dendritic branching. *Mol Brain* **2**: 30.
- Ludolph AC, Brettschneider J. 2015. TDP-43 in amyotrophic lateral sclerosis—Is it a prion disease? *Eur J Neurol* **22**: 753–761.
- Luk KC, Kehm V, Carroll J, Zhang B, O'Brien P, Trojanowski JQ, Lee VM. 2012. Pathological α -synuclein transmission initiates Parkinson-like neurodegeneration in nontransgenic mice. *Science* **338**: 949–953.
- Lukavsky PJ, Daujotyte D, Tollervy JR, Ule J, Stuaní C, Buratti E, Baralle FE, Damberger FF, Allain FH. 2013. Molecular basis of UG-rich RNA recognition by the human splicing factor TDP-43. *Nat Struct Mol Biol* **20**: 1443–1449.
- Mackenzie IR, Neumann M. 2012. FET proteins in frontotemporal dementia and amyotrophic lateral sclerosis. *Brain Res* **1462**: 40–43.
- * Mackenzie IRA, Neumann M. 2017. Fused in sarcoma neuropathology in neurodegenerative disease. *Cold Spring Harb Perspect Med* doi: 10.1101/cshperspect.a024299.
- Mackenzie IR, Bigio EH, Ince PG, Geser F, Neumann M, Cairns NJ, Kwong LK, Forman MS, Ravits J, Stewart H, et al. 2007. Pathological TDP-43 distinguishes sporadic amyotrophic lateral sclerosis from amyotrophic lateral sclerosis with SOD1 mutations. *Ann Neurol* **61**: 427–434.
- Mackenzie IR, Rademakers R, Neumann M. 2010. TDP-43 and FUS in amyotrophic lateral sclerosis and frontotemporal dementia. *Lancet Neurol* **9**: 995–1007.
- Mackenzie IR, Arzberger T, Kremmer E, Troost D, Lorenz S, Mori K, Weng SM, Haass C, Kretschmar HA, Edbauer D, et al. 2013. Dipeptide repeat protein pathology in C9orf72 mutation cases: Clinico-pathological correlations. *Acta Neuropathol* **126**: 859–879.
- Madsen L, Schulze A, Seeger M, Hartmann-Petersen R. 2007. Ubiquitin domain proteins in disease. *BMC Biochem* **8**: S1.
- Majumdar A, Cesario WC, White-Grindley E, Jiang H, Ren F, Khan MR, Li L, Choi EM, Kannan K, Guo F, et al. 2012. Critical role of amyloid-like oligomers of *Drosophila* Orb2 in the persistence of memory. *Cell* **148**: 515–529.
- Mangus DA, Amrani N, Jacobson A. 1998. Pbp1p, a factor interacting with *Saccharomyces cerevisiae* poly(A)-binding protein, regulates polyadenylation. *Mol Cell Biol* **18**: 7383–7396.
- Maniecka Z, Polymenidou M. 2015. From nucleation to widespread propagation: A prion-like concept for ALS. *Virus Res* **207**: 94–105.
- March ZM, King OD, Shorter J. 2016. Prion-like domains as epigenetic regulators, scaffolds for subcellular organization, and drivers of neurodegenerative disease. *Brain Res* **1647**: 9–18.
- Mattoo RU, Sharma SK, Priya S, Finka A, Goloubinoff P. 2013. Hsp110 is a bona fide chaperone using ATP to unfold stable misfolded polypeptides and reciprocally collaborate with Hsp70 to solubilize protein aggregates. *J Biol Chem* **288**: 21399–21411.
- May S, Hornburg D, Schludi MH, Arzberger T, Rentzsch K, Schwenk BM, Grasser FA, Mori K, Kremmer E, Banzhaf-Strathmann J, et al. 2014. C9orf72 FTL/ALS-associated Gly-Ala dipeptide repeat proteins cause neuronal toxicity and Unc119 sequestration. *Acta Neuropathol* **128**: 485–503.
- McDonald KK, Aulas A, Destroismaisons L, Pickles S, Beleac E, Camu W, Rouleau GA, Vande Velde C. 2011. TAR DNA-binding protein 43 (TDP-43) regulates stress granule dynamics via differential regulation of G3BP and TIA-1. *Hum Mol Genet* **20**: 1400–1410.
- Mizielinska S, Gronke S, Niccoli T, Ridler CE, Clayton EL, Devoy A, Moens T, Norona FE, Woollacott IO, Pietrzyk J, et al. 2014. C9orf72 repeat expansions cause neurodegeneration in *Drosophila* through arginine-rich proteins. *Science* **345**: 1192–1194.
- Molliex A, Temirov J, Lee J, Coughlin M, Kanagaraj AP, Kim HJ, Mittag T, Taylor JP. 2015. Phase separation by low complexity domains promotes stress granule assembly and drives pathological fibrillization. *Cell* **163**: 123–133.
- Mompean M, Romano V, Pantoja-Uceda D, Stuaní C, Baralle FE, Buratti E, Laurents DV. 2016. The TDP-43 N-terminal domain structure at high resolution. *FEBS J* **283**: 1242–1260.
- Moreno JA, Radford H, Peretti D, Steinert JR, Verity N, Martin MG, Halliday M, Morgan J, Dinsdale D, Ortori CA, et al. 2012. Sustained translational repression by eIF2 α -P mediates prion neurodegeneration. *Nature* **485**: 507–511.
- Moreno JA, Halliday M, Molloy C, Radford H, Verity N, Axten JM, Ortori CA, Willis AE, Fischer PM, Barrett DA, et al. 2013. Oral treatment targeting the unfolded protein response prevents neurodegeneration and clinical disease in prion-infected mice. *Sci Transl Med* **5**: 206ra138.
- Mori K, Arzberger T, Grasser FA, Gijssels I, May S, Rentzsch K, Weng SM, Schludi MH, van der Zee J, Cruts M, et al. 2013a. Bidirectional transcripts of the expanded C9orf72 hexanucleotide repeat are translated into aggregating dipeptide repeat proteins. *Acta Neuropathol* **126**: 881–893.
- Mori K, Lammich S, Mackenzie IR, Forne I, Zilow S, Kretschmar H, Edbauer D, Janssens J, Kleinberger G, Cruts M, et al. 2013b. hnRNP A3 binds to GGGGCC repeats and is a constituent of p62-positive/TDP43-negative inclusions in the hippocampus of patients with C9orf72 mutations. *Acta Neuropathol* **125**: 413–423.
- Mori K, Weng SM, Arzberger T, May S, Rentzsch K, Kremmer E, Schmid B, Kretschmar HA, Cruts M, Van Broeckhoven C, et al. 2013c. The C9orf72 GGGGCC repeat is translated into aggregating dipeptide-repeat proteins in FTL/ALS. *Science* **339**: 1335–1338.
- Mu TW, Ong DS, Wang YJ, Balch WE, Yates JR III, Segatori L, Kelly JW. 2008. Chemical and biological approaches synergize to ameliorate protein-folding diseases. *Cell* **134**: 769–781.
- Nakashima-Yasuda H, Uryu K, Robinson J, Xie SX, Hurtig H, Duda JE, Arnold SE, Siderowf A, Grossman M, Leventer JB, et al. 2007. Co-morbidity of TDP-43 proteinopathy in Lewy body related diseases. *Acta Neuropathol* **114**: 221–229.

L. Guo and J. Shorter

- Nencetti S, Rossello A, Orlandini E. 2013. Tafamidis (Vyn-daquel): A light for FAP patients. *ChemMedChem* **8**: 1617–1619.
- Neumann M, Sampathu DM, Kwong LK, Truax AC, Micsenyi MC, Chou TT, Bruce J, Schuck T, Grossman M, Clark CM, et al. 2006. Ubiquitinated TDP-43 in frontotemporal lobar degeneration and amyotrophic lateral sclerosis. *Science* **314**: 130–133.
- Neumann M, Kwong LK, Sampathu DM, Trojanowski JQ, Lee VM. 2007. TDP-43 proteinopathy in frontotemporal lobar degeneration and amyotrophic lateral sclerosis: Protein misfolding diseases without amyloidosis. *Arch Neurol* **64**: 1388–1394.
- Neumann M, Rademakers R, Roeder S, Baker M, Kretschmar HA, Mackenzie IR. 2009. A new subtype of frontotemporal lobar degeneration with FUS pathology. *Brain* **132**: 2922–2931.
- Neumann M, Bentmann E, Dormann D, Jawaid A, DeJesus-Hernandez M, Ansorge O, Roeder S, Kretschmar HA, Munoz DG, Kusaka H, et al. 2011. FET proteins TAF15 and EWS are selective markers that distinguish FTLD with FUS pathology from amyotrophic lateral sclerosis with FUS mutations. *Brain* **134**: 2595–2609.
- Nillegoda NB, Kirstein J, Szlachcic A, Berynskyy M, Stank A, Stengel F, Arnsburg K, Gao X, Scior A, Aebersold R, et al. 2015. Crucial HSP70 co-chaperone complex unlocks metazoan protein disaggregation. *Nature* **524**: 247–251.
- Nishimoto Y, Ito D, Yagi T, Nihei Y, Tsunoda Y, Suzuki N. 2010. Characterization of alternative isoforms and inclusion body of the TAR DNA-binding protein-43. *J Biol Chem* **285**: 608–619.
- Nonaka T, Hasegawa M. 2017. TDP-43 prions. *Cold Spring Harb Perspect Med* doi: 10.1101/cshperspect.a024463.
- Nonaka T, Masuda-Suzukake M, Arai T, Hasegawa Y, Akatsu H, Obi T, Yoshida M, Murayama S, Mann DM, Akiyama H, et al. 2013. Prion-like properties of pathological TDP-43 aggregates from diseased brains. *Cell Rep* **4**: 124–134.
- Ou SH, Wu F, Harrich D, Garcia-Martinez LF, Gaynor RB. 1995. Cloning and characterization of a novel cellular protein, TDP-43, that binds to human immunodeficiency virus type 1 TAR DNA sequence motifs. *J Virol* **69**: 3584–3596.
- Pasinelli P, Brown RH. 2006. Molecular biology of amyotrophic lateral sclerosis: Insights from genetics. *Nat Rev Neurosci* **7**: 710–723.
- Paul JW, Gitler AD. 2014. Cell biology. Clogging information flow in ALS. *Science* **345**: 1118–1119.
- Pesiridis GS, Lee VM, Trojanowski JQ. 2009. Mutations in TDP-43 link glycine-rich domain functions to amyotrophic lateral sclerosis. *Hum Mol Genet* **18**: R156–R162.
- Pesiridis GS, Tripathy K, Tanik S, Trojanowski JQ, Lee VM. 2011. A “two-hit” hypothesis for inclusion formation by carboxyl-terminal fragments of TDP-43 protein linked to RNA depletion and impaired microtubule-dependent transport. *J Biol Chem* **286**: 18845–18855.
- Polymenidou M, Cleveland DW. 2011. The seeds of neurodegeneration: Prion-like spreading in ALS. *Cell* **147**: 498–508.
- Polymenidou M, Cleveland DW. 2012. Prion-like spread of protein aggregates in neurodegeneration. *J Exp Med* **209**: 889–893.
- Polymenidou M, Lagier-Tourenne C, Hutt KR, Huelga SC, Moran J, Liang TY, Ling SC, Sun E, Wanciewicz E, Mazur C, et al. 2011. Long pre-mRNA depletion and RNA mis-splicing contribute to neuronal vulnerability from loss of TDP-43. *Nat Neurosci* **14**: 459–468.
- Prusiner SB. 2013. Biology and genetics of prions causing neurodegeneration. *Annu Rev Genet* **47**: 601–623.
- Pulst SM, Nechiporuk A, Nechiporuk T, Gispert S, Chen XN, Lopes-Cendes I, Pearlman S, Starkman S, Orozco-Diaz G, Lunkes A, et al. 1996. Moderate expansion of a normally biallelic trinucleotide repeat in spinocerebellar ataxia type 2. *Nat Genet* **14**: 269–276.
- Qin H, Lim LZ, Wei Y, Song J. 2014. TDP-43 N terminus encodes a novel ubiquitin-like fold and its unfolded form in equilibrium that can be shifted by binding to ssDNA. *Proc Natl Acad Sci* **111**: 18619–18624.
- Rademakers R, Stewart H, DeJesus-Hernandez M, Krieger C, Graff-Radford N, Fabros M, Briemberg H, Cashman N, Eisen A, Mackenzie IR. 2010. FUS gene mutations in familial and sporadic amyotrophic lateral sclerosis. *Muscle Nerve* **42**: 170–176.
- Ramaswami M, Taylor JP, Parker R. 2013. Altered ribostasis: RNA-protein granules in degenerative disorders. *Cell* **154**: 727–736.
- Rampelt H, Kirstein-Miles J, Nillegoda NB, Chi K, Scholz SR, Morimoto RI, Bukau B. 2012. Metazoan Hsp70 machines use Hsp110 to power protein disaggregation. *EMBO J* **31**: 4221–4235.
- Ravits JM, La Spada AR. 2009. ALS motor phenotype heterogeneity, focality, and spread: Deconstructing motor neuron degeneration. *Neurology* **73**: 805–811.
- Renton AE, Majounie E, Waite A, Simon-Sanchez J, Rollinson S, Gibbs JR, Schymick JC, Laaksovirta H, van Swieten JC, Myllykangas L, et al. 2011. A hexanucleotide repeat expansion in C9ORF72 is the cause of chromosome 9p21-linked ALS-FTD. *Neuron* **72**: 257–268.
- Renton AE, Chio A, Traynor BJ. 2014. State of play in amyotrophic lateral sclerosis genetics. *Nat Neurosci* **17**: 17–23.
- Ritson GP, Custer SK, Freibaum BD, Guinto JB, Geffell D, Moore J, Tang W, Winton MJ, Neumann M, Trojanowski JQ, et al. 2010. TDP-43 mediates degeneration in a novel *Drosophila* model of disease caused by mutations in VCP/p97. *J Neurosci* **30**: 7729–7739.
- Robberecht W, Philips T. 2013. The changing scene of amyotrophic lateral sclerosis. *Nat Rev Neurosci* **14**: 248–264.
- Roberts BE, Duennwald ML, Wang H, Chung C, Lopreiato NP, Sweeney EA, Knight MN, Shorter J. 2009. A synergistic small-molecule combination directly eradicates diverse prion strain structures. *Nat Chem Biol* **5**: 936–946.
- Robinson JL, Geser F, Stieber A, Umoh M, Kwong LK, Van Deerlin VM, Lee VM, Trojanowski JQ. 2013. TDP-43 skeins show properties of amyloid in a subset of ALS cases. *Acta Neuropathol* **125**: 121–131.
- Rohrer JD, Isaacs AM, Mizielinska S, Mead S, Lashley T, Wray S, Sidle K, Fratta P, Orrell RW, Hardy J, et al. 2015. C9orf72 expansions in frontotemporal dementia and amyotrophic lateral sclerosis. *Lancet Neurol* **14**: 291–301.
- Romano V, Quadri Z, Baralle FE, Buratti E. 2015. The structural integrity of TDP-43 N-terminus is required for ef-

- efficient aggregate entrapment and consequent loss of protein function. *Prion* **9**: 1–9.
- Rotunno MS, Bosco DA. 2013. An emerging role for misfolded wild-type SOD1 in sporadic ALS pathogenesis. *Front Cell Neurosci* **7**: 253.
- Rowland LP, Shneider NA. 2001. Amyotrophic lateral sclerosis. *N Engl J Med* **344**: 1688–1700.
- Saini A, Chauhan VS. 2011. Delineation of the core aggregation sequences of TDP-43 C-terminal fragment. *Chem-biochem* **12**: 2495–2501.
- Saini A, Chauhan VS. 2014. Self-assembling properties of peptides derived from TDP-43 C-terminal fragment. *Langmuir* **30**: 3845–3856.
- Saldi TK, Ash PE, Wilson G, Gonzales P, Garrido-Lecca A, Roberts CM, Dostal V, Gendron TF, Stein LD, Blumenthal T, et al. 2014. TDP-1, the *Caenorhabditis elegans* ortholog of TDP-43, limits the accumulation of double-stranded RNA. *EMBO J* **33**: 2947–2966.
- Schmidt HB, Rohatgi R. 2016. In vivo formation of vacuolated multi-phase compartments lacking membranes. *Cell Rep* **16**: 1228–1236.
- Schmid B, Hruscha A, Hög S, Banzhaf-Strathmann J, Strecker K, van der Zee J, Teucke M, Eimer S, Hegemann J, Kittelmann M, et al. 2013. Loss of ALS-associated TDP-43 in zebrafish causes muscle degeneration, vascular dysfunction, and reduced motor neuron axon outgrowth. *Proc Natl Acad Sci* **110**: 4986–4991.
- Schwab C, Arai T, Hasegawa M, Yu S, McGeer PL. 2008. Colocalization of transactivation-responsive DNA-binding protein 43 and huntingtin in inclusions of Huntington disease. *J Neuropathol Exp Neurol* **67**: 1159–1165.
- Scotter EL, Vance C, Nishimura AL, Lee YB, Chen HJ, Urwin H, Sardone V, Mitchell JC, Rogelj B, Rubinsztein DC, et al. 2014. Differential roles of the ubiquitin proteasome system and autophagy in the clearance of soluble and aggregated TDP-43 species. *J Cell Sci* **127**: 1263–1278.
- Seelaar H, Schelhaas HJ, Azmani A, Kusters B, Rosso S, Majoor-Krakauer D, de Rijk MC, Rizzo P, ten Brummelhuis M, van Doorn PA, et al. 2007. TDP-43 pathology in familial frontotemporal dementia and motor neuron disease without Progranulin mutations. *Brain* **130**: 1375–1385.
- Seelaar H, Klijnsma KY, de Koning I, van der Lugt A, Chiu WZ, Azmani A, Rozemuller AJ, van Swieten JC. 2010. Frequency of ubiquitin and FUS-positive, TDP-43-negative frontotemporal lobar degeneration. *J Neurol* **257**: 747–753.
- Sephton CF, Good SK, Atkin S, Dewey CM, Mayer P III, Herz J, Yu G. 2010. TDP-43 is a developmentally regulated protein essential for early embryonic development. *J Biol Chem* **285**: 6826–6834.
- Sephton CF, Cenik C, Kucukural A, Dammer EB, Cenik B, Han Y, Dewey CM, Roth FP, Herz J, Peng J, et al. 2011. Identification of neuronal RNA targets of TDP-43-containing ribonucleoprotein complexes. *J Biol Chem* **286**: 1204–1215.
- Shaw CE. 2010. Capturing VCP: Another molecular piece in the ALS jigsaw puzzle. *Neuron* **68**: 812–814.
- Shiina Y, Arima K, Tabunoki H, Satoh J. 2010. TDP-43 dimerizes in human cells in culture. *Cell Mol Neurobiol* **30**: 641–652.
- Shorter J. 2008. Hsp104: A weapon to combat diverse neurodegenerative disorders. *Neurosignals* **16**: 63–74.
- Shorter J. 2010. Emergence and natural selection of drug-resistant prions. *Mol Biosyst* **6**: 1115–1130.
- Shorter J. 2011. The mammalian disaggregase machinery: Hsp110 synergizes with Hsp70 and Hsp40 to catalyze protein disaggregation and reactivation in a cell-free system. *PLoS ONE* **6**: e26319.
- Shorter J. 2016. Engineering therapeutic protein disaggregases. *Mol Biol Cell* **27**: 1556–1560.
- Shorter J, Lindquist S. 2005. Prions as adaptive conduits of memory and inheritance. *Nat Rev Genet* **6**: 435–450.
- Shorter J, Taylor JP. 2013. Disease mutations in the prion-like domains of hnRNPA1 and hnRNPA2/B1 introduce potent steric zippers that drive excess RNP granule assembly. *Rare Dis* **1**: e25200.
- Si K, Giustetto M, Etkin A, Hsu R, Janisiewicz AM, Miniaci MC, Kim JH, Zhu H, Kandel ER. 2003a. A neuronal isoform of CPEB regulates local protein synthesis and stabilizes synapse-specific long-term facilitation in aplysia. *Cell* **115**: 893–904.
- Si K, Lindquist S, Kandel ER. 2003b. A neuronal isoform of the aplysia CPEB has prion-like properties. *Cell* **115**: 879–891.
- Si K, Choi YB, White-Grindley E, Majumdar A, Kandel ER. 2010. Aplysia CPEB can form prion-like multimers in sensory neurons that contribute to long-term facilitation. *Cell* **140**: 421–435.
- Sidrauski C, Acosta-Alvear D, Khoutorsky A, Vedantham P, Hearn BR, Li H, Gamache K, Gallagher CM, Ang KK, Wilson C, et al. 2013. Pharmacological brake-release of mRNA translation enhances cognitive memory. *eLife* **2**: e00498.
- Sidrauski C, McGeachy AM, Ingolia NT, Walter P. 2015. The small molecule ISRIB reverses the effects of eIF2 α phosphorylation on translation and stress granule assembly. *eLife* **4**: e05033.
- Sreedharan J, Blair IP, Tripathi VB, Hu X, Vance C, Rogelj B, Ackerley S, Durnall JC, Williams KL, Buratti E, et al. 2008. TDP-43 mutations in familial and sporadic amyotrophic lateral sclerosis. *Science* **319**: 1668–1672.
- Stephan JS, Fioriti L, Lamba N, Colnaghi L, Karl K, Derkatch IL, Kandel ER. 2015. The CPEB3 protein is a functional prion that interacts with the actin cytoskeleton. *Cell Rep* **11**: 1772–1785.
- Sun S, Cleveland DW. 2012. TDP-43 toxicity and the usefulness of junk. *Nat Genet* **44**: 1289–1291.
- Sun Z, Diaz Z, Fang X, Hart MP, Chesi A, Shorter J, Gitler AD. 2011. Molecular determinants and genetic modifiers of aggregation and toxicity for the ALS disease protein FUS/TLS. *PLoS Biol* **9**: e1000614.
- Sun Y, Arslan PE, Won A, Yip CM, Chakrabartty A. 2014. Binding of TDP-43 to the 3'UTR of its cognate mRNA enhances its solubility. *Biochemistry* **53**: 5885–5894.
- Sweeny EA, Jackrel ME, Go MS, Sochor MA, Razzo BM, DeSantis ME, Gupta K, Shorter J. 2015. The hsp104 N-terminal domain enables disaggregase plasticity and potentiation. *Mol Cell* **57**: 836–849.
- Tan CE, Eguchi H, Tagawa A, Onodera O, Iwasaki T, Tsujino A, Nishizawa M, Kakita A, Takahashi H. 2007. TDP-43 immunoreactivity in neuronal inclusions in familial

TDP-43: Biology, Pathobiology, and Therapeutics

L. Guo and J. Shorter

- amyotrophic lateral sclerosis with or without SOD1 gene mutation. *Acta Neuropathol* **113**: 535–542.
- Tao Z, Wang H, Xia Q, Li K, Li K, Jiang X, Xu G, Wang G, Ying Z. 2015. Nucleolar stress and impaired stress granule formation contribute to C9orf72 RAN translation-induced cytotoxicity. *Hum Mol Genet* **24**: 2426–2441.
- Thomas MG, Loschi M, Desbats MA, Boccaccio GL. 2011. RNA granules: The good, the bad and the ugly. *Cell Signal* **23**: 324–334.
- Tollervey JR, Curk T, Rogelj B, Briesse M, Cereda M, Kayikci M, Konig J, Hortobagyi T, Nishimura AL, Zupunski V, et al. 2011. Characterizing the RNA targets and position-dependent splicing regulation by TDP-43. *Nat Neurosci* **14**: 452–458.
- Torrente MP, Shorter J. 2013. The metazoan protein disaggregase and amyloid depolymerase system: Hsp110, Hsp70, Hsp40, and small heat shock proteins. *Prion* **7**: 457–463.
- Torrente MP, Chuang E, Noll MM, Jackrel ME, Go MS, Shorter J. 2016. Mechanistic insights into Hsp104 potentiation. *J Biol Chem* **291**: 5101–5115.
- Tran H, Almeida S, Moore J, Gendron TF, Chalasani U, Lu Y, Du X, Nickerson JA, Petrucelli L, Weng Z, et al. 2015. Differential toxicity of nuclear RNA foci versus dipeptide repeat proteins in a *Drosophila* model of C9ORF72 FTD/ALS. *Neuron* **87**: 1207–1214.
- Tsai KJ, Yang CH, Fang YH, Cho KH, Chien WL, Wang WT, Wu TW, Lin CP, Fu WM, Shen CK. 2010. Elevated expression of TDP-43 in the forebrain of mice is sufficient to cause neurological and pathological phenotypes mimicking FTLD-U. *J Exp Med* **207**: 1661–1673.
- Tsaytler P, Harding HP, Ron D, Bertolotti A. 2011. Selective inhibition of a regulatory subunit of protein phosphatase 1 restores proteostasis. *Science* **332**: 91–94.
- Udan M, Baloh RH. 2011. Implications of the prion-related Q/N domains in TDP-43 and FUS. *Prion* **5**: 1–5.
- Uryu K, Nakashima-Yasuda H, Forman MS, Kwong LK, Clark CM, Grossman M, Miller BL, Kretschmar HA, Lee VM, Trojanowski JQ, et al. 2008. Concomitant TAR-DNA-binding protein 43 pathology is present in Alzheimer disease and corticobasal degeneration but not in other tauopathies. *J Neuropathol Exp Neurol* **67**: 555–564.
- Vaccaro A, Patten SA, Aggad D, Julien C, Maios C, Kabashi E, Drapeau P, Parker JA. 2013. Pharmacological reduction of ER stress protects against TDP-43 neuronal toxicity in vivo. *Neurobiol Dis* **55**: 64–75.
- Valentine JS, Hart PJ. 2003. Misfolded CuZnSOD and amyotrophic lateral sclerosis. *Proc Natl Acad Sci* **100**: 3617–3622.
- Vance C, Rogelj B, Hortobagyi T, De Vos KJ, Nishimura AL, Sreedharan J, Hu X, Smith B, Ruddy D, Wright P, et al. 2009. Mutations in FUS, an RNA processing protein, cause familial amyotrophic lateral sclerosis type 6. *Science* **323**: 1208–1211.
- Vieira NM, Naslavsky MS, Licinio L, Kok F, Schlesinger D, Vainzof M, Sanchez N, Kitajima JP, Gal L, Cavacana N, et al. 2014. A defect in the RNA-processing protein HNRPD1 causes limb-girdle muscular dystrophy 1G (LGMD1G). *Hum Mol Genet* **23**: 4103–4110.
- Voigt A, Herholz D, Fiesel FC, Kaur K, Muller D, Karsten P, Weber SS, Kahle PJ, Marquardt T, Schulz JB. 2010. TDP-43-mediated neuron loss in vivo requires RNA-binding activity. *PLoS ONE* **5**: e12247.
- Wainwright CE, Elborn JS, Ramsey BW, Marigowda G, Huang X, Cipolli M, Colombo C, Davies JC, De Boeck K, Flume PA, et al. 2015. Lumacaftor–Ivacaftor in patients with cystic fibrosis homozygous for Phe508del CFTR. *N Engl J Med* **373**: 220–231.
- Walker AK, Daniels CM, Goldman JE, Trojanowski JQ, Lee VM, Messing A. 2014. Astrocytic TDP-43 pathology in Alexander disease. *J Neurosci* **34**: 6448–6458.
- Walters RW, Muhlrud D, Garcia J, Parker R. 2015. Differential effects of Ydj1 and Sis1 on Hsp70-mediated clearance of stress granules in *Saccharomyces cerevisiae*. *RNA* **21**: 1660–1671.
- Wang F, Wang X, Yuan CG, Ma J. 2010. Generating a prion with bacterially expressed recombinant prion protein. *Science* **327**: 1132–1135.
- Wang F, Wang X, Ma J. 2011a. Conversion of bacterially expressed recombinant prion protein. *Methods* **53**: 208–213.
- Wang F, Zhang Z, Wang X, Li J, Zha L, Yuan CG, Weissmann C, Ma J. 2011b. Genetic informational RNA is not required for recombinant prion infectivity. *J Virol* **86**: 1874–1876.
- Wang IF, Chang HY, Hou SC, Liou GG, Way TD, James Shen CK. 2012. The self-interaction of native TDP-43 C terminus inhibits its degradation and contributes to early proteinopathies. *Nat Commun* **3**: 766.
- Wang YT, Kuo PH, Chiang CH, Liang JR, Chen YR, Wang S, Shen JC, Yuan HS. 2013. The truncated C-terminal RNA recognition motif of TDP-43 protein plays a key role in forming proteinaceous aggregates. *J Biol Chem* **288**: 9049–9057.
- Weihl CC, Temiz P, Miller SE, Watts G, Smith C, Forman M, Hanson PJ, Kimonis V, Pestronk A. 2008. TDP-43 accumulation in inclusion body myopathy muscle suggests a common pathogenic mechanism with frontotemporal dementia. *J Neurol Neurosurg Psychiatry* **79**: 1186–1189.
- Wen X, Tan W, Westergard T, Krishnamurthy K, Markandiah SS, Shi Y, Lin S, Shneider NA, Monaghan J, Pandey UB, et al. 2014. Antisense proline-arginine RAN dipeptides linked to C9ORF72-ALS/FTD form toxic nuclear aggregates that initiate in vitro and in vivo neuronal death. *Neuron* **84**: 1213–1225.
- Winton MJ, Igaz LM, Wong MM, Kwong LK, Trojanowski JQ, Lee VM. 2008. Disturbance of nuclear and cytoplasmic TAR DNA-binding protein (TDP-43) induces disease-like redistribution, sequestration, and aggregate formation. *J Biol Chem* **283**: 13302–13309.
- Wu LS, Cheng WC, Shen CK. 2012. Targeted depletion of TDP-43 expression in the spinal cord motor neurons leads to the development of amyotrophic lateral sclerosis-like phenotypes in mice. *J Biol Chem* **287**: 27335–27344.
- Xu YF, Gendron TF, Zhang YJ, Lin WL, D’Alton S, Sheng H, Casey MC, Tong J, Knight J, Yu X, et al. 2010. Wild-type human TDP-43 expression causes TDP-43 phosphorylation, mitochondrial aggregation, motor deficits, and early mortality in transgenic mice. *J Neurosci* **30**: 10851–10859.

- Yang C, Tan W, Whittle C, Qiu L, Cao L, Akbarian S, Xu Z. 2010. The C-terminal TDP-43 fragments have a high aggregation propensity and harm neurons by a dominant-negative mechanism. *PLoS ONE* **5**: e15878.
- Yu Z, Zhu Y, Chen-Plotkin AS, Clay-Falcone D, McCluskey L, Elman L, Kalb RG, Trojanowski JQ, Lee VM, Van Deerlin VM, et al. 2011. PolyQ repeat expansions in ATXN2 associated with ALS are CAA interrupted repeats. *PLoS ONE* **6**: e17951.
- Zhang YJ, Xu YF, Cook C, Gendron TF, Roettges P, Link CD, Lin WL, Tong J, Castaneda-Casey M, Ash P, et al. 2009. Aberrant cleavage of TDP-43 enhances aggregation and cellular toxicity. *Proc Natl Acad Sci* **106**: 7607–7612.
- Zhang T, Mullane PC, Periz G, Wang J. 2011. TDP-43 neurotoxicity and protein aggregation modulated by heat shock factor and insulin/IGF-1 signaling. *Hum Mol Genet* **20**: 1952–1965.
- Zhang T, Hwang HY, Hao H, Talbot C Jr, Wang J. 2012. *Caenorhabditis elegans* RNA-processing protein TDP-1 regulates protein homeostasis and life span. *J Biol Chem* **287**: 8371–8382.
- Zhang YJ, Caulfield T, Xu YF, Gendron TF, Hubbard J, Stetler C, Sasaguri H, Whitelaw EC, Cai S, Lee WC, et al. 2013. The dual functions of the extreme N-terminus of TDP-43 in regulating its biological activity and inclusion formation. *Hum Mol Genet* **22**: 3112–3122.
- Zhang K, Donnelly CJ, Haeusler AR, Grima JC, Machamer JB, Steinwald P, Daley EL, Miller SJ, Cunningham KM, Vidensky S, et al. 2015. The C9orf72 repeat expansion disrupts nucleocytoplasmic transport. *Nature* **525**: 56–61.
- Zinman L, Cudkowicz M. 2011. Emerging targets and treatments in amyotrophic lateral sclerosis. *Lancet Neurol* **10**: 481–490.
- Zu T, Gibbens B, Doty NS, Gomes-Pereira M, Huguet A, Stone MD, Margolis J, Peterson M, Markowski TW, Ingram MA, et al. 2011. Non-ATG-initiated translation directed by microsatellite expansions. *Proc Natl Acad Sci* **108**: 260–265.
- Zu T, Liu Y, Banez-Coronel M, Reid T, Pletnikova O, Lewis J, Miller TM, Harms MB, Falchook AE, Subramony SH, et al. 2013. RAN proteins and RNA foci from antisense transcripts in C9ORF72 ALS and frontotemporal dementia. *Proc Natl Acad Sci* **110**: E4968–E4977.

TDP-43: Biology, Pathobiology, and Therapeutics

Biology and Pathobiology of TDP-43 and Emergent Therapeutic Strategies

Lin Guo and James Shorter

Cold Spring Harb Perspect Med 2017; doi: 10.1101/cshperspect.a024554 originally published online December 5, 2016

Subject Collection [Prion Diseases](#)

TDP-43 Prions

Takashi Nonaka and Masato Hasegawa

α -Synuclein: Multiple System Atrophy Prions

Amanda L. Woerman, Joel C. Watts, Atsushi Aoyagi, et al.

Genetics of Synucleinopathies

Robert L. Nussbaum

β -Amyloid Prions and the Pathobiology of Alzheimer's Disease

Joel C. Watts and Stanley B. Prusiner

Disease Mechanisms of C9ORF72 Repeat Expansions

Tania F. Gendron and Leonard Petrucelli

Chronic Traumatic Encephalopathy: Is Latency in Symptom Onset Explained by Tau Propagation?

Joshua Kriegel, Zachary Papadopoulos and Ann C. McKee

Noncerebral Amyloidoses: Aspects on Seeding, Cross-Seeding, and Transmission

Gunilla T. Westermark, Marcus Fändrich, Katarzyna Lundmark, et al.

Structural and Chemical Biology of Presenilin Complexes

Douglas S. Johnson, Yue-Ming Li, Martin Pettersson, et al.

Cell Biology and Pathophysiology of α -Synuclein

Jacqueline Burré, Manu Sharma and Thomas C. Südhof

Molecular Mechanisms of Chronic Wasting Disease Prion Propagation

Julie A. Moreno and Glenn C. Telling

Genetics of Amyotrophic Lateral Sclerosis

Mehdi Ghasemi and Robert H. Brown, Jr.

The Genetics of C9orf72 Expansions

Ilse Gijssels, Marc Cruts and Christine Van Broeckhoven

Prion-Like Characteristics of Polyglutamine-Containing Proteins

Margaret M.P. Pearce and Ron R. Kopito

Therapeutic Strategies for Restoring Tau Homeostasis

Zapporah T. Young, Sue Ann Mok and Jason E. Gestwicki

Fused in Sarcoma Neuropathology in Neurodegenerative Disease

Ian R.A. Mackenzie and Manuela Neumann

Experimental Models of Inherited PrP Prion Diseases

Joel C. Watts and Stanley B. Prusiner

For additional articles in this collection, see <http://perspectivesinmedicine.cshlp.org/cgi/collection/>